drug1_db stringlengths 7 7 | drug2_db stringlengths 7 7 | drug1_id int64 0 1.69k | drug2_id int64 0 1.69k | drug_pair listlengths 2 2 | drug1_name stringlengths 4 85 | drug2_name stringlengths 4 85 | drug1_desc stringlengths 27 1.09k | drug2_desc stringlengths 27 6.14k | label stringclasses 3
values | label_idx int64 0 2 | all_paths listlengths 1 10 | all_paths_str listlengths 1 10 | path_str stringlengths 0 3.57k |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
DB06603 | DB06699 | 39 | 774 | [
"DDInter1387",
"DDInter493"
] | Panobinostat | Degarelix | Panobinostat is an oral deacetylace (DAC) inhibitor approved on February 23, 2015 by the FDA for the treatment of multiple myeloma. The approval was accelerated based on progression-free survival, therefore confirmatory trials by the sponsor to demonstrate clinical efficacy in multiple myeloma treatment are in progress... | Degarelix is used for the treatment of advanced prostate cancer. Degarelix is a synthetic peptide derivative drug which binds to gonadotropin-releasing hormone (GnRH) receptors in the pituitary gland and blocks interaction with GnRH. This antagonism reduces luteinising hormone (LH) and follicle-stimulating hormone (FSH... | Major | 2 | [
[
[
39,
25,
774
]
],
[
[
39,
64,
521
],
[
521,
1,
774
]
],
[
[
39,
62,
112
],
[
112,
23,
774
]
],
[
[
39,
64,
888
],
[
888,
24,
... | [
[
[
"Panobinostat",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Degarelix"
]
],
[
[
"Panobinostat",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Goserelin"
],
[
"Goserelin",
"{u} ... | Panobinostat may lead to a major life threatening interaction when taken with Goserelin and Goserelin (Compound) resembles Degarelix (Compound)
Panobinostat may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical... |
DB00196 | DB09389 | 600 | 517 | [
"DDInter743",
"DDInter1315"
] | Fluconazole | Norgestrel | Fluconazole, commonly known as _Diflucan_, is an antifungal drug used for the treatment of both systemic and superficial fungal infections in a variety of tissues. It was initially approved by the FDA in 1990. This drug is an _azole_ antifungal, in the same drug family as [ketoconazole] and [itraconazole]. Fluconazole ... | Norgestrel is synthetic steroidal progestin that is used in combination with ethinyl estradiol for oral contraception. Norgestrel is composed of a racemic mixture of two stereoisomers, dextronorgestrel and levonorgestrel. However, only the levorotary enantiomer ([levonorgestrel]) is biologically active. | Moderate | 1 | [
[
[
600,
24,
517
]
],
[
[
600,
23,
14
],
[
14,
23,
517
]
],
[
[
600,
24,
159
],
[
159,
63,
517
]
],
[
[
600,
24,
86
],
[
86,
24,
... | [
[
[
"Fluconazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Norgestrel"
]
],
[
[
"Fluconazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Rosuvastatin"
],
[
... | Fluconazole may cause a minor interaction that can limit clinical effects when taken with Rosuvastatin and Rosuvastatin may cause a minor interaction that can limit clinical effects when taken with Norgestrel
Fluconazole may cause a moderate interaction that could exacerbate diseases when taken with Larotrectinib and L... |
DB00284 | DB04946 | 1,647 | 924 | [
"DDInter11",
"DDInter907"
] | Acarbose | Iloperidone | Acarbose is a complex oligosaccharide that acts as an inhibitor of several enzymes responsible for the breakdown of complex carbohydrates in the intestines. It inhibits both pancreatic alpha-amylase and membrane-bound alpha-glucosidases - including intestinal glucoamylase, sucrase, maltase, and isomaltase - which are r... | Iloperidone is an atypical antipsychotic for the treatment of schizophrenia symptoms. Hoechst Marion Roussel Inc. researched the drug until May 1996. In June 1997 they gave the research rights to Titan Pharmaceuticals, who gave the worldwide development, manufacturing, and marketing rights to Novartis in August 1998. O... | Moderate | 1 | [
[
[
1647,
24,
924
]
],
[
[
1647,
24,
1664
],
[
1664,
1,
924
]
],
[
[
1647,
24,
519
],
[
519,
40,
924
]
],
[
[
1647,
21,
28809
],
[
28809,
... | [
[
[
"Acarbose",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Iloperidone"
]
],
[
[
"Acarbose",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Risperidone"
],
[
... | Acarbose may cause a moderate interaction that could exacerbate diseases when taken with Risperidone and Risperidone (Compound) resembles Iloperidone (Compound)
Acarbose may cause a moderate interaction that could exacerbate diseases when taken with Paliperidone and Paliperidone (Compound) resembles Iloperidone (Compou... |
DB00214 | DB09038 | 1,028 | 1,450 | [
"DDInter1836",
"DDInter636"
] | Torasemide | Empagliflozin | Torasemide is a high-ceiling loop diuretic. Structurally, it is a pyridine-sulfonylurea used as an antihypertensive agent. Torasemide was first approved for clinical use by the FDA in 1993. | Empagliflozin is an inhibitor of sodium-glucose co-transporter-2 (SGLT2), the transporters primarily responsible for the reabsorption of glucose in the kidney. It is used clinically as an adjunct to diet and exercise, often in combination with other drug therapies,[L13673,L13679,L11479] for the management of type 2 dia... | Moderate | 1 | [
[
[
1028,
24,
1450
]
],
[
[
1028,
24,
659
],
[
659,
63,
1450
]
],
[
[
1028,
24,
1061
],
[
1061,
24,
1450
]
],
[
[
1028,
63,
1179
],
[
1179... | [
[
[
"Torasemide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Empagliflozin"
]
],
[
[
"Torasemide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vilanterol"
],
[... | Torasemide may cause a moderate interaction that could exacerbate diseases when taken with Vilanterol and Vilanterol may cause a moderate interaction that could exacerbate diseases when taken with Empagliflozin
Torasemide may cause a moderate interaction that could exacerbate diseases when taken with Treprostinil and T... |
DB01115 | DB09112 | 336 | 1,455 | [
"DDInter1291",
"DDInter1306"
] | Nifedipine | Nitrous acid | Nifedipine, or BAY a 1040, is a first generation dihydropyridine L-type calcium channel blocker, similar to [nicardipine].[A190210,A190273,A175390,L11383] Nifedipine was developed by Bayer and first described in the literature, along with other dihydropyridines, in 1972.[A175390,A190276] Since nifedipine's development,... | Nitrous acid (as sodium nitrite) is used as part of an intravenous mixture with sodium thiosulfate to treat cyanide poisoning. It is on the World Health Organization's List of Essential Medicines, a list of the most important medications needed in a basic health system. There is also research to investigate its applica... | Moderate | 1 | [
[
[
336,
24,
1455
]
],
[
[
336,
24,
1450
],
[
1450,
24,
1455
]
],
[
[
336,
40,
84
],
[
84,
24,
1455
]
],
[
[
336,
63,
714
],
[
714,
... | [
[
[
"Nifedipine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nitrous acid"
]
],
[
[
"Nifedipine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Empagliflozin"
],
... | Nifedipine may cause a moderate interaction that could exacerbate diseases when taken with Empagliflozin and Empagliflozin may cause a moderate interaction that could exacerbate diseases when taken with Nitrous acid
Nifedipine (Compound) resembles Nisoldipine (Compound) and Nisoldipine may cause a moderate interaction ... |
DB06605 | DB09048 | 1,409 | 555 | [
"DDInter108",
"DDInter1284"
] | Apixaban | Netupitant | Apixaban is an oral, direct, and highly selective factor Xa (FXa) inhibitor of both free and bound FXa, as well as prothrombinase, independent of antithrombin III for the prevention and treatment of thromboembolic diseases[Label,A6897]. It is marketed under the name Eliquis[Label,L6043]. Apixaban was approved by the FD... | Netupitant is an antiemitic drug approved by the FDA in October 2014 for use in combination with palonosetron for the prevention of acute and delayed vomiting and nausea associated with cancer chemotherapy including highly emetogenic chemotherapy. Netupitant is a neurokinin 1 receptor antagonist. The combination drug i... | Moderate | 1 | [
[
[
1409,
24,
555
]
],
[
[
1409,
63,
1101
],
[
1101,
23,
555
]
],
[
[
1409,
24,
283
],
[
283,
62,
555
]
],
[
[
1409,
25,
760
],
[
760,
... | [
[
[
"Apixaban",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Netupitant"
]
],
[
[
"Apixaban",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bexarotene"
],
[
... | Apixaban may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene and Bexarotene may cause a minor interaction that can limit clinical effects when taken with Netupitant
Apixaban may cause a moderate interaction that could exacerbate diseases when taken with Fedratinib and Fedratinib m... |
DB06016 | DB08865 | 1,508 | 1,593 | [
"DDInter300",
"DDInter448"
] | Cariprazine | Crizotinib | Cariprazine is an atypical antipsychotic agent and a piperazine derivative that was first developed in Hungary. It works as a partial agonist at central dopamine D2, dopamine D3, and serotonin 5-HT<sub>1A</sub> receptors and as an antagonist at serotonin 5-HT<sub>2A</sub> receptors. Cariprazine has been investigated in... | Crizotinib is a tyrosine kinase receptor inhibitor used for the treatment of anaplastic lymphoma kinase (ALK) or ROS1-positive non-small cell lung cancer (NSCLC) tumors, as well as ALK-positive anaplastic large cell lymphoma (ALCL) and inflammatory myofibroblastic tumor (IMT). By targeting the echinoderm microtubule-as... | Moderate | 1 | [
[
[
1508,
24,
1593
]
],
[
[
1508,
24,
283
],
[
283,
62,
1593
]
],
[
[
1508,
63,
86
],
[
86,
24,
1593
]
],
[
[
1508,
24,
159
],
[
159,
... | [
[
[
"Cariprazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Crizotinib"
]
],
[
[
"Cariprazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fedratinib"
],
[
... | Cariprazine may cause a moderate interaction that could exacerbate diseases when taken with Fedratinib and Fedratinib may cause a minor interaction that can limit clinical effects when taken with Crizotinib
Cariprazine may cause a moderate interaction that could exacerbate diseases when taken with Miconazole and Micona... |
DB00312 | DB09054 | 1,023 | 384 | [
"DDInter1423",
"DDInter905"
] | Pentobarbital | Idelalisib | A short-acting barbiturate that is effective as a sedative and hypnotic (but not as an anti-anxiety) agent and is usually given orally. It is prescribed more frequently for sleep induction than for sedation but, like similar agents, may lose its effectiveness by the second week of continued administration. (From AMA Dr... | Idelalisib is a phosphoinositide 3-kinase inhibitor indicated in the treatment of chronic lymphocytic leukemia (CLL), relapsed follicular B-cell non-Hodgkin lymphoma (FL), and relapsed small lymphocytic lymphoma (SLL). For the treatment of relapsed CLL, it is currently indicated as a second-line agent in combination wi... | Moderate | 1 | [
[
[
1023,
24,
384
]
],
[
[
1023,
24,
222
],
[
222,
23,
384
]
],
[
[
1023,
24,
1618
],
[
1618,
24,
384
]
],
[
[
1023,
62,
1101
],
[
1101,
... | [
[
[
"Pentobarbital",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Idelalisib"
]
],
[
[
"Pentobarbital",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sibutramine"
],
... | Pentobarbital may cause a moderate interaction that could exacerbate diseases when taken with Sibutramine and Sibutramine may cause a minor interaction that can limit clinical effects when taken with Idelalisib
Pentobarbital may cause a moderate interaction that could exacerbate diseases when taken with Cabozantinib an... |
DB00375 | DB00586 | 1,037 | 1,512 | [
"DDInter433",
"DDInter537"
] | Colestipol | Diclofenac | Bile acid sequestrants like colestipol have been in use since the 1970s.[FDA Label, F4555, F4567, L6262] And even though such an agent may very well be useful in reducing elevated cholesterol levels and decreasing the risk for atherosclerotic vascular disease due to hypercholesterolemia, colestipol is still generally o... | Diclofenac is a phenylacetic acid derivative and non-steroidal anti-inflammatory drug (NSAID).[label] NSAIDs inhibit cyclooxygenase (COX)-1 and-2 which are the enzyme responsible for producing prostaglandins (PGs). PGs contribute to inflammation and pain signalling. Diclofenac, like other NSAIDs, is often used as first... | Minor | 0 | [
[
[
1037,
23,
1512
]
],
[
[
1037,
21,
29231
],
[
29231,
60,
1512
]
],
[
[
1037,
24,
1486
],
[
1486,
63,
1512
]
],
[
[
1037,
25,
1510
],
[
... | [
[
[
"Colestipol",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Diclofenac"
]
],
[
[
"Colestipol",
"{u} (Compound) causes {v} (Side Effect)",
"Cardiac disorder"
],
[
"Cardiac disorder",
"{u} (Side Eff... | Colestipol (Compound) causes Cardiac disorder (Side Effect) and Cardiac disorder (Side Effect) is caused by Diclofenac (Compound)
Colestipol may cause a moderate interaction that could exacerbate diseases when taken with Methylprednisolone and Methylprednisolone may cause a moderate interaction that could exacerbate di... |
DB05239 | DB09065 | 866 | 760 | [
"DDInter425",
"DDInter424"
] | Cobimetinib | Cobicistat | Cobimetinib is an orally active, potent and highly selective small molecule inhibiting mitogen-activated protein kinase kinase 1 (MAP2K1 or MEK1), and central components of the RAS/RAF/MEK/ERK signal transduction pathway. It has been approved in Switzerland and the US, in combination with vemurafenib for the treatment ... | Cobicistat, marketed under the name Tybost (formerly GS-9350), indicated for treating infection with human immunodeficiency virus (HIV). Although it does not have any anti-HIV activity, cobicistat acts as a pharmacokinetic enhancer by inhibiting cytochrome P450 3A isoforms (CYP3A) and therefore increases the systemic e... | Major | 2 | [
[
[
866,
25,
760
]
],
[
[
866,
24,
1627
],
[
1627,
23,
760
]
],
[
[
866,
63,
1101
],
[
1101,
23,
760
]
],
[
[
866,
25,
555
],
[
555,
... | [
[
[
"Cobimetinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cobicistat"
]
],
[
[
"Cobimetinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cannabidiol"
],
[
"Cannabi... | Cobimetinib may cause a moderate interaction that could exacerbate diseases when taken with Cannabidiol and Cannabidiol may cause a minor interaction that can limit clinical effects when taken with Cobicistat
Cobimetinib may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene and Bexa... |
DB00681 | DB04855 | 1,287 | 540 | [
"DDInter85",
"DDInter602"
] | Amphotericin B | Dronedarone | Amphotericin B shows a high order of in vitro activity against many species of fungi. Histoplasma capsulatum, Coccidioides immitis, Candida species, Blastomyces dermatitidis, Rhodotorula, Cryptococcus neoformans, Sporothrix schenckii, Mucor mucedo, and Aspergillus fumigatus are all inhibited by concentrations of amphot... | Dronedarone is a Class III antiarrhythmic drug that works to restore the normal sinus rhythm in patients with paroxysmal or persistent atrial fibrillation. Atrial fibrillation is a common sustained arrhythmia where the treatment primarily focuses on stroke prevention and symptom management. It is managed by rate contro... | Major | 2 | [
[
[
1287,
25,
540
]
],
[
[
1287,
64,
228
],
[
228,
40,
540
]
],
[
[
1287,
25,
33
],
[
33,
40,
540
]
],
[
[
1287,
21,
28883
],
[
28883,
... | [
[
[
"Amphotericin B",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dronedarone"
]
],
[
[
"Amphotericin B",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dofetilide"
],
[
"Dofetilide",
... | Amphotericin B may lead to a major life threatening interaction when taken with Dofetilide and Dofetilide (Compound) resembles Dronedarone (Compound)
Amphotericin B may lead to a major life threatening interaction when taken with Amiodarone and Amiodarone (Compound) resembles Dronedarone (Compound)
Amphotericin B (Comp... |
DB01618 | DB09268 | 776 | 1,662 | [
"DDInter1239",
"DDInter1464"
] | Molindone | Picosulfuric acid | An indole derivative effective in schizophrenia and other psychoses and possibly useful in the treatment of the aggressive type of undersocialized conduct disorder. Molindone has much lower affinity for D2 receptors than most antipsychotic agents and has a relatively low affinity for D1 receptors. It has only low to mo... | Picosulfuric acid is found in laxative products. Sodium picosulfate is a used to treat constipation or induce colon cleansing to prepare the large bowels before colonoscopy or surgery. The combination product containing sodium picosulfate and magnesium citrate was introduced to the Canadian market in 2005 and has been ... | Moderate | 1 | [
[
[
776,
24,
1662
]
],
[
[
776,
63,
820
],
[
820,
24,
1662
]
],
[
[
776,
64,
475
],
[
475,
24,
1662
]
],
[
[
776,
24,
407
],
[
407,
... | [
[
[
"Molindone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Picosulfuric acid"
]
],
[
[
"Molindone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alimemazine"
],
... | Molindone may cause a moderate interaction that could exacerbate diseases when taken with Alimemazine and Alimemazine may cause a moderate interaction that could exacerbate diseases when taken with Picosulfuric acid
Molindone may lead to a major life threatening interaction when taken with Morphine and Morphine may cau... |
DB00909 | DB01211 | 306 | 609 | [
"DDInter1971",
"DDInter393"
] | Zonisamide | Clarithromycin | Zonisamide is a sulfonamide anticonvulsant used as an adjunctive therapy in adults with partial-onset seizures.[L42530,L42535] Zonisamide may act by blocking repetitive firing of voltage-gated sodium channels, leading to a reduction of T-type calcium channel currents or by binding allosterically to GABA receptors. This... | Clarithromycin, a semisynthetic macrolide antibiotic derived from erythromycin, inhibits bacterial protein synthesis by binding to the bacterial 50S ribosomal subunit. Binding inhibits peptidyl transferase activity and interferes with amino acid translocation during the translation and protein assembly process. Clarith... | Moderate | 1 | [
[
[
306,
24,
609
]
],
[
[
306,
6,
10215
],
[
10215,
45,
609
]
],
[
[
306,
54,
19133
],
[
19133,
15,
609
]
],
[
[
306,
21,
28879
],
[
28879... | [
[
[
"Zonisamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clarithromycin"
]
],
[
[
"Zonisamide",
"{u} (Compound) binds {v} (Gene)",
"CYP2C19"
],
[
"CYP2C19",
"{u} (Gene) is bound by {v} (Compo... | Zonisamide (Compound) binds CYP2C19 (Gene) and CYP2C19 (Gene) is bound by Clarithromycin (Compound)
Zonisamide (Compound) is included by P-Glycoprotein Inhibitors (Pharmacologic Class) and P-Glycoprotein Inhibitors (Pharmacologic Class) includes Clarithromycin (Compound)
Zonisamide (Compound) causes Gingival bleeding (... |
DB00635 | DB09098 | 1,573 | 98 | [
"DDInter1515",
"DDInter1700"
] | Prednisone | Somatrem | A synthetic anti-inflammatory glucocorticoid derived from [cortisone]. It is biologically inert and converted to [prednisolone] in the liver. Prednisone was granted FDA approval on 21 February 1955. | Despite the ability of almost all contemporary recombinant growth hormones to cause definite and demonstrable increases in growth rate in patients who are administered the drug, the use of these agents continues to be mired in persistent bioethical debate . Such discussion revolves around whether patients' natural disp... | Moderate | 1 | [
[
[
1573,
24,
98
]
],
[
[
1573,
24,
336
],
[
336,
24,
98
]
],
[
[
1573,
24,
159
],
[
159,
63,
98
]
],
[
[
1573,
63,
1433
],
[
1433,
... | [
[
[
"Prednisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Somatrem"
]
],
[
[
"Prednisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nifedipine"
],
[
... | Prednisone may cause a moderate interaction that could exacerbate diseases when taken with Nifedipine and Nifedipine may cause a moderate interaction that could exacerbate diseases when taken with Somatrem
Prednisone may cause a moderate interaction that could exacerbate diseases when taken with Larotrectinib and Larot... |
DB00701 | DB01166 | 1,091 | 477 | [
"DDInter90",
"DDInter379"
] | Amprenavir | Cilostazol | Amprenavir is a protease inhibitor used to treat HIV infection. | Cilostazol is a quinolinone derivative and antiplatelet agent with vasodilating properties that has been used in the symptomatic treatment of intermittent claudication in patients with peripheral ischaemia. It is marketed under the brand name Pletal by Otsuka Pharmaceutical Co.. Cilostazol works by inhibiting both prim... | Major | 2 | [
[
[
1091,
25,
477
]
],
[
[
1091,
6,
8374
],
[
8374,
45,
477
]
],
[
[
1091,
21,
29340
],
[
29340,
60,
477
]
],
[
[
1091,
25,
112
],
[
112,
... | [
[
[
"Amprenavir",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cilostazol"
]
],
[
[
"Amprenavir",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Cilosta... | Amprenavir (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Cilostazol (Compound)
Amprenavir (Compound) causes Stevens-Johnson syndrome (Side Effect) and Stevens-Johnson syndrome (Side Effect) is caused by Cilostazol (Compound)
Amprenavir may lead to a major life threatening interaction when taken with Metr... |
DB01067 | DB01579 | 959 | 341 | [
"DDInter826",
"DDInter1439"
] | Glipizide | Phendimetrazine | Glipizide is an oral hypoglycemic agent in the second-generation sulfonylurea drug class that is used to control blood sugar levels in patients with type 2 diabetes mellitus. It was first introduced in 1984 and is available in various countries including Canada and the U.S. According to the 2018 Clinical Practice Guide... | Phendimetrazine is a weight loss medication. Phendimetrazine is chemically related to amphetamines and is a Schedule III drug under the Convention on Psychotropic Substances and in the US since 1970. | Moderate | 1 | [
[
[
959,
24,
341
]
],
[
[
959,
21,
28662
],
[
28662,
60,
341
]
],
[
[
959,
24,
1281
],
[
1281,
63,
341
]
],
[
[
959,
24,
401
],
[
401,
... | [
[
[
"Glipizide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phendimetrazine"
]
],
[
[
"Glipizide",
"{u} (Compound) causes {v} (Side Effect)",
"Tremor"
],
[
"Tremor",
"{u} (Side Effect) is caused ... | Glipizide (Compound) causes Tremor (Side Effect) and Tremor (Side Effect) is caused by Phendimetrazine (Compound)
Glipizide may cause a moderate interaction that could exacerbate diseases when taken with Linagliptin and Linagliptin may cause a moderate interaction that could exacerbate diseases when taken with Phendime... |
DB00451 | DB00731 | 542 | 1,144 | [
"DDInter1064",
"DDInter1269"
] | Levothyroxine | Nateglinide | Levothyroxine is a synthetically produced form of thyroxine, a major endogenous hormone secreted by the thyroid gland. Also known as L-thyroxine or the brand name product Synthroid, levothyroxine is used primarily to treat hypothyroidism, a condition where the thyroid gland is no longer able to produce sufficient quant... | Nateglinide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It belongs to the meglitinide class of short-acting insulin secretagogues, which act by binding to β cells of the pancreas to stimulate insulin release. Nateglinide is an amino acid derivative that ... | Moderate | 1 | [
[
[
542,
24,
1144
]
],
[
[
542,
63,
80
],
[
80,
40,
1144
]
],
[
[
542,
24,
93
],
[
93,
40,
1144
]
],
[
[
542,
6,
1829
],
[
1829,
45,... | [
[
[
"Levothyroxine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nateglinide"
]
],
[
[
"Levothyroxine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Amphetamine"
],
... | Levothyroxine may cause a moderate interaction that could exacerbate diseases when taken with Amphetamine and Amphetamine (Compound) resembles Nateglinide (Compound)
Levothyroxine may cause a moderate interaction that could exacerbate diseases when taken with Dextroamphetamine and Dextroamphetamine (Compound) resembles... |
DB00348 | DB00814 | 254 | 1,171 | [
"DDInter1300",
"DDInter1143"
] | Nitisinone | Meloxicam | Nitisinone is a synthetic reversible inhibitor of 4-hydroxyphenylpyruvate dioxygenase. It is used in the treatment of hereditary tyrosinemia type 1. It is sold under the brand name Orfadin. | Meloxicam is a nonsteroidal anti-inflammatory drug (NSAID) used to relieve various types of pain, including pain caused by musculoskeletal conditions, osteoarthritis, and rheumatoid arthritis. With a longer half-life than most other NSAIDS, it is a favorable option for those who require once-daily dosing. Meloxicam is ... | Moderate | 1 | [
[
[
254,
24,
1171
]
],
[
[
254,
24,
1027
],
[
1027,
40,
1171
]
],
[
[
254,
21,
29005
],
[
29005,
60,
1171
]
],
[
[
254,
24,
1604
],
[
1604... | [
[
[
"Nitisinone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Meloxicam"
]
],
[
[
"Nitisinone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Piroxicam"
],
[
... | Nitisinone may cause a moderate interaction that could exacerbate diseases when taken with Piroxicam and Piroxicam (Compound) resembles Meloxicam (Compound)
Nitisinone (Compound) causes Dermatitis exfoliative (Side Effect) and Dermatitis exfoliative (Side Effect) is caused by Meloxicam (Compound)
Nitisinone may cause a... |
DB01234 | DB11640 | 1,220 | 1,267 | [
"DDInter513",
"DDInter64"
] | Dexamethasone | Amifampridine | Dexamethasone, or MK-125, is a corticosteroid fluorinated at position 9 used to treat endocrine, rheumatic, collagen, dermatologic, allergic, ophthalmic, gastrointestinal, respiratory, hematologic, neoplastic, edematous, and other conditions. Developed in 1957, it is structurally similar to other corticosteroids like [... | Amifampridine, or 3,4-diaminopyridine (3,4-DAP), is a quaternary ammonium compound that blocks presynaptic potassium channels, and subsequently prolongs the action potential and increases presynaptic calcium concentrations . It was first discovered in Scotland in the 1970s and its clinical effectiveness for neuromuscul... | Moderate | 1 | [
[
[
1220,
24,
1267
]
],
[
[
1220,
1,
1486
],
[
1486,
24,
1267
]
],
[
[
1220,
63,
1010
],
[
1010,
24,
1267
]
],
[
[
1220,
40,
870
],
[
870,... | [
[
[
"Dexamethasone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Amifampridine"
]
],
[
[
"Dexamethasone",
"{u} (Compound) resembles {v} (Compound)",
"Methylprednisolone"
],
[
"Methylprednisolone",
... | Dexamethasone (Compound) resembles Methylprednisolone (Compound) and Methylprednisolone may cause a moderate interaction that could exacerbate diseases when taken with Amifampridine
Dexamethasone may cause a moderate interaction that could exacerbate diseases when taken with Mefloquine and Mefloquine may cause a modera... |
DB00850 | DB06655 | 1,630 | 5 | [
"DDInter1432",
"DDInter1077"
] | Perphenazine | Liraglutide | An antipsychotic phenothiazine derivative with actions and uses similar to those of chlorpromazine. | Victoza contains liraglutide, a synthetic analog of human glucagon-like peptide-1(GLP-1) and acts as a GLP-1 receptor agonist.[Label,A6932] Liraglutide is 97% similar to native human GLP-1, differing primarily by substituting arginine for lysine at position 34. Liraglutide is made by attaching a C-16 fatty acid (palmit... | Moderate | 1 | [
[
[
1630,
24,
5
]
],
[
[
1630,
63,
245
],
[
245,
24,
5
]
],
[
[
1630,
24,
480
],
[
480,
24,
5
]
],
[
[
1630,
1,
9
],
[
9,
24,
... | [
[
[
"Perphenazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Liraglutide"
]
],
[
[
"Perphenazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glimepiride"
],
... | Perphenazine may cause a moderate interaction that could exacerbate diseases when taken with Glimepiride and Glimepiride may cause a moderate interaction that could exacerbate diseases when taken with Liraglutide
Perphenazine may cause a moderate interaction that could exacerbate diseases when taken with Formoterol and... |
DB00213 | DB11828 | 837 | 1,406 | [
"DDInter1388",
"DDInter1281"
] | Pantoprazole | Neratinib | Pantoprazole is a first-generation proton pump inhibitor (PPI) used for the management of gastroesophageal reflux disease (GERD), for gastric protection to prevent recurrence of stomach ulcers or gastric damage from chronic use of NSAIDs, and for the treatment of pathological hypersecretory conditions including Zolling... | Neratinib was approved in July 2017 for use as an extended adjuvant therapy in Human Epidermal Growth Factor Receptor 2 (HER2) positive breast cancer. Approval was granted to Puma Biotechnology Inc. for the tradename Nerlynx. Neratinib is currently under investigation for use in many other forms of cancer. | Major | 2 | [
[
[
837,
25,
1406
]
],
[
[
837,
24,
392
],
[
392,
24,
1406
]
],
[
[
837,
25,
1195
],
[
1195,
24,
1406
]
],
[
[
837,
24,
1375
],
[
1375,
... | [
[
[
"Pantoprazole",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Neratinib"
]
],
[
[
"Pantoprazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lapatinib"
],
[
"Lapatini... | Pantoprazole may cause a moderate interaction that could exacerbate diseases when taken with Lapatinib and Lapatinib may cause a moderate interaction that could exacerbate diseases when taken with Neratinib
Pantoprazole may lead to a major life threatening interaction when taken with Erlotinib and Erlotinib may cause a... |
DB12941 | DB14575 | 466 | 733 | [
"DDInter481",
"DDInter674"
] | Darolutamide | Eslicarbazepine | Darolutamide is a nonsteroidal androgen receptor antagonist for the treatment of castrate-resistant, non-metastatic prostate cancer (nmCRPC). This condition occurs in the majority of patients with advanced prostate cancer who have been treated with androgen receptor antagonists. Though prior treatment for prostate canc... | Eslicarbazepine is an anti-epileptic medication available commercially as [eslicarbazepine acetate]. | Moderate | 1 | [
[
[
466,
24,
733
]
],
[
[
466,
63,
1101
],
[
1101,
23,
733
]
],
[
[
466,
62,
351
],
[
351,
24,
733
]
],
[
[
466,
63,
710
],
[
710,
2... | [
[
[
"Darolutamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Eslicarbazepine"
]
],
[
[
"Darolutamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bexarotene"
],... | Darolutamide may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene and Bexarotene may cause a minor interaction that can limit clinical effects when taken with Eslicarbazepine
Darolutamide may cause a minor interaction that can limit clinical effects when taken with Ribociclib and R... |
DB01064 | DB11796 | 1,148 | 1,612 | [
"DDInter987",
"DDInter786"
] | Isoprenaline | Fostemsavir | Isoprenaline is a non-selective beta adrenergic receptor agonist indicated to treat heart block, Adams-Stokes attacks, bronchospasm in anesthesia, cadiac arrest, hypovolemic shocks, septic shock, hypoperfusion, congestive hear failure, and cardiogenic shock.[A15638,L33160] Isoprenaline research in the 1940s found that ... | Fostemsavir is the phosphonooxymethyl prodrug of temsavir, a novel HIV-1 attachment inhibitor. It binds to and inhibits the activity of gp120, a subunit within the HIV-1 gp160 envelope glycoprotein that facilitates the attachment of HIV-1 to host cell CD4 receptors - in doing so, temsavir prevents the first step in the... | Moderate | 1 | [
[
[
1148,
24,
1612
]
],
[
[
1148,
63,
1324
],
[
1324,
23,
1612
]
],
[
[
1148,
23,
1220
],
[
1220,
23,
1612
]
],
[
[
1148,
63,
1424
],
[
14... | [
[
[
"Isoprenaline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fostemsavir"
]
],
[
[
"Isoprenaline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Troglitazone"
],
... | Isoprenaline may cause a moderate interaction that could exacerbate diseases when taken with Troglitazone and Troglitazone may cause a minor interaction that can limit clinical effects when taken with Fostemsavir
Isoprenaline may cause a minor interaction that can limit clinical effects when taken with Dexamethasone an... |
DB00585 | DB06209 | 1,127 | 256 | [
"DDInter1309",
"DDInter1508"
] | Nizatidine | Prasugrel | A histamine H2 receptor antagonist with low toxicity that inhibits gastric acid secretion. The drug is used for the treatment of duodenal ulcers. | Prasugrel, a thienopyridine derivative, is a platelet activation and aggregation inhibitor structurally and pharmacologically related to clopidogrel and ticlopidine. Similar to clopidogrel, prasugrel is a prodrug that requires enzymatic transformation in the liver to its active metabolite, R-138727. R-138727 irreversib... | Minor | 0 | [
[
[
1127,
23,
256
]
],
[
[
1127,
21,
28792
],
[
28792,
60,
256
]
],
[
[
1127,
1,
1194
],
[
1194,
23,
256
]
],
[
[
1127,
62,
109
],
[
109,
... | [
[
[
"Nizatidine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Prasugrel"
]
],
[
[
"Nizatidine",
"{u} (Compound) causes {v} (Side Effect)",
"Gastrointestinal disorder"
],
[
"Gastrointestinal disorder",
... | Nizatidine (Compound) causes Gastrointestinal disorder (Side Effect) and Gastrointestinal disorder (Side Effect) is caused by Prasugrel (Compound)
Nizatidine (Compound) resembles Ranitidine (Compound) and Ranitidine may cause a minor interaction that can limit clinical effects when taken with Prasugrel
Nizatidine may c... |
DB01144 | DB11113 | 1,326 | 657 | [
"DDInter540",
"DDInter307"
] | Diclofenamide | Castor oil | A carbonic anhydrase inhibitor that is used in the treatment of glaucoma. | Castor oil is a vegetable oil obtained by pressing the seeds of the castor oil plant (_Ricinus communis_ L.) mainly cultivated in India, South America, Africa, and China. Castor oil is a rich source of , which represents up to 90% of the total castor oil content. It also consists up to 4% linoleic, 3% oleic, 1% stearic... | Moderate | 1 | [
[
[
1326,
24,
657
]
],
[
[
1326,
63,
891
],
[
891,
24,
657
]
],
[
[
1326,
24,
708
],
[
708,
24,
657
]
],
[
[
1326,
1,
674
],
[
674,
... | [
[
[
"Diclofenamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Castor oil"
]
],
[
[
"Diclofenamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Prednisolone"
],
... | Diclofenamide may cause a moderate interaction that could exacerbate diseases when taken with Prednisolone and Prednisolone may cause a moderate interaction that could exacerbate diseases when taken with Castor oil
Diclofenamide may cause a moderate interaction that could exacerbate diseases when taken with Corticotrop... |
DB09036 | DB11248 | 812 | 1,193 | [
"DDInter1668",
"DDInter1965"
] | Siltuximab | Zinc gluconate | Siltuximab is a chimeric (human-mouse) monoclonal immunoglobulin G1-kappa antibody produced in a Chinese hamster ovary (CHO) cell line by recombinant DNA technology. Siltuximab prevents the binding of IL-6 to soluble and membrane-bound IL-6 receptors by forming high affinity complexes with human interleukin-6 (IL-6). I... | Zinc gluconate is a zinc salt of gluconic acid comprised of two gluconic acid molecules for each zinc cation (2+). Zinc gluconate is a generally recognized as safe (GRAS) substance by FDA . It is available as a trace mineral supplement and over the counter as a lozenge form for a reduced duration of common colds and wi... | Minor | 0 | [
[
[
812,
23,
1193
]
],
[
[
812,
63,
1531
],
[
1531,
23,
1193
]
],
[
[
812,
24,
270
],
[
270,
62,
1193
]
],
[
[
812,
25,
1259
],
[
1259,
... | [
[
[
"Siltuximab",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Zinc gluconate"
]
],
[
[
"Siltuximab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Canakinumab"
],
[... | Siltuximab may cause a moderate interaction that could exacerbate diseases when taken with Canakinumab and Canakinumab may cause a minor interaction that can limit clinical effects when taken with Zinc gluconate
Siltuximab may cause a moderate interaction that could exacerbate diseases when taken with Ocrelizumab and O... |
DB01234 | DB06817 | 1,220 | 809 | [
"DDInter513",
"DDInter1563"
] | Dexamethasone | Raltegravir | Dexamethasone, or MK-125, is a corticosteroid fluorinated at position 9 used to treat endocrine, rheumatic, collagen, dermatologic, allergic, ophthalmic, gastrointestinal, respiratory, hematologic, neoplastic, edematous, and other conditions. Developed in 1957, it is structurally similar to other corticosteroids like [... | Raltegravir is an antiretroviral drug produced by Merck & Co., used to treat HIV infection. It received approval by the U.S. Food and Drug Administration (FDA) on 12 October 2007, the first of a new class of HIV drugs, the integrase inhibitors, to receive such approval. | Minor | 0 | [
[
[
1220,
23,
809
]
],
[
[
1220,
7,
3418
],
[
3418,
46,
809
]
],
[
[
1220,
21,
31004
],
[
31004,
60,
809
]
],
[
[
1220,
25,
478
],
[
478,
... | [
[
[
"Dexamethasone",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Raltegravir"
]
],
[
[
"Dexamethasone",
"{u} (Compound) upregulates {v} (Gene)",
"HSPB1"
],
[
"HSPB1",
"{u} (Gene) is upregulated by {... | Dexamethasone (Compound) upregulates HSPB1 (Gene) and HSPB1 (Gene) is upregulated by Raltegravir (Compound)
Dexamethasone (Compound) causes Dermatitis acneiform (Side Effect) and Dermatitis acneiform (Side Effect) is caused by Raltegravir (Compound)
Dexamethasone may lead to a major life threatening interaction when ta... |
DB00802 | DB01069 | 1,322 | 401 | [
"DDInter43",
"DDInter1533"
] | Alfentanil | Promethazine | A short-acting opioid anesthetic and analgesic derivative of fentanyl. It produces an early peak analgesic effect and fast recovery of consciousness. Alfentanil is effective as an anesthetic during surgery, for supplementation of analgesia during surgical procedures, and as an analgesic for critically ill patients. | Promethazine, originally known as 3,277 R.P., is an N-dimethylaminopropyl derivative of [phenothiazine] that was developed in France in 1946. Promethazine antagonizes a variety of receptors, allowing it to be used for a number of indications including allergic reactions, pain, sedation, nausea, and vomiting.[A189907,A1... | Moderate | 1 | [
[
[
1322,
24,
401
]
],
[
[
1322,
24,
1264
],
[
1264,
63,
401
]
],
[
[
1322,
24,
104
],
[
104,
24,
401
]
],
[
[
1322,
6,
4973
],
[
4973,
... | [
[
[
"Alfentanil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Promethazine"
]
],
[
[
"Alfentanil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxepin"
],
[
... | Alfentanil may cause a moderate interaction that could exacerbate diseases when taken with Doxepin and Doxepin may cause a moderate interaction that could exacerbate diseases when taken with Promethazine
Alfentanil may cause a moderate interaction that could exacerbate diseases when taken with Methdilazine and Methdila... |
DB00700 | DB09112 | 312 | 1,455 | [
"DDInter656",
"DDInter1306"
] | Eplerenone | Nitrous acid | Eplerenone, an aldosterone receptor antagonist similar to spironolactone, has been shown to produce sustained increases in plasma renin and serum aldosterone, consistent with inhibition of the negative regulatory feedback of aldosterone on renin secretion. The resulting increased plasma renin activity and aldosterone c... | Nitrous acid (as sodium nitrite) is used as part of an intravenous mixture with sodium thiosulfate to treat cyanide poisoning. It is on the World Health Organization's List of Essential Medicines, a list of the most important medications needed in a basic health system. There is also research to investigate its applica... | Moderate | 1 | [
[
[
312,
24,
1455
]
],
[
[
312,
24,
1450
],
[
1450,
24,
1455
]
],
[
[
312,
24,
433
],
[
433,
63,
1455
]
],
[
[
312,
40,
443
],
[
443,
... | [
[
[
"Eplerenone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nitrous acid"
]
],
[
[
"Eplerenone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Empagliflozin"
],
... | Eplerenone may cause a moderate interaction that could exacerbate diseases when taken with Empagliflozin and Empagliflozin may cause a moderate interaction that could exacerbate diseases when taken with Nitrous acid
Eplerenone may cause a moderate interaction that could exacerbate diseases when taken with Ertugliflozin... |
DB00620 | DB06414 | 175 | 655 | [
"DDInter1855",
"DDInter703"
] | Triamcinolone | Etravirine | Triamcinolone is a corticosteroid used to treat various inflammatory conditions in the body from allergic rhinitis to acute exacerbations of multiple sclerosis. Triamcinolone can be used as a one time adjunct treatment of osteoarthritic knee pain, or first line as a topical treatment of corticosteroid responsive dermat... | Etravirine is an antiretroviral agent more specifically classified as a Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI). Etraverine is used clinically for the treatment of human immunodeficiency virus type 1 (HIV-1) infection. On January 18, 2007, the FDA granted accelerated approved for the use of etravirine 10... | Moderate | 1 | [
[
[
175,
24,
655
]
],
[
[
175,
6,
8374
],
[
8374,
45,
655
]
],
[
[
175,
21,
28680
],
[
28680,
60,
655
]
],
[
[
175,
63,
1101
],
[
1101,
... | [
[
[
"Triamcinolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Etravirine"
]
],
[
[
"Triamcinolone",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compo... | Triamcinolone (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Etravirine (Compound)
Triamcinolone (Compound) causes Rash (Side Effect) and Rash (Side Effect) is caused by Etravirine (Compound)
Triamcinolone may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene and Bexar... |
DB00023 | DB09054 | 305 | 384 | [
"DDInter127",
"DDInter905"
] | Asparaginase Escherichia coli | Idelalisib | Asparaginase derived from _Escherichia coli_ (L-asparagine amidohydrolase, EC 3.5.1.1) is an enzyme responsible for the metabolism of L-asparagine, by catalyzing L-asparagine into L-aspartic acid and ammonia. It also facilitates the production of oxaloacetate which is needed for general cellular metabolism. Asparaginas... | Idelalisib is a phosphoinositide 3-kinase inhibitor indicated in the treatment of chronic lymphocytic leukemia (CLL), relapsed follicular B-cell non-Hodgkin lymphoma (FL), and relapsed small lymphocytic lymphoma (SLL). For the treatment of relapsed CLL, it is currently indicated as a second-line agent in combination wi... | Moderate | 1 | [
[
[
305,
24,
384
]
],
[
[
305,
24,
1627
],
[
1627,
62,
384
]
],
[
[
305,
24,
72
],
[
72,
24,
384
]
],
[
[
305,
24,
725
],
[
725,
63,... | [
[
[
"Asparaginase Escherichia coli",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Idelalisib"
]
],
[
[
"Asparaginase Escherichia coli",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v... | Asparaginase Escherichia coli may cause a moderate interaction that could exacerbate diseases when taken with Cannabidiol and Cannabidiol may cause a minor interaction that can limit clinical effects when taken with Idelalisib
Asparaginase Escherichia coli may cause a moderate interaction that could exacerbate diseases... |
DB00332 | DB00502 | 1,089 | 1,300 | [
"DDInter970",
"DDInter853"
] | Ipratropium | Haloperidol | Ipratropium is a quaternary ammonium derivative of [atropine] that acts as an anticholinergic agent. It is commonly administered through inhalation which allows producing a local effect without presenting a significant systemic absorption. Ipratropium as a therapeutic agent was developed by Boehringer Ingelheim and its... | Haloperidol is a high potency first-generation (typical) antipsychotic and one of the most frequently used antipsychotic medications used worldwide. While haloperidol has demonstrated pharmacologic activity at a number of receptors in the brain, it exerts its antipsychotic effect through its strong antagonism of the do... | Moderate | 1 | [
[
[
1089,
24,
1300
]
],
[
[
1089,
6,
8374
],
[
8374,
45,
1300
]
],
[
[
1089,
21,
28779
],
[
28779,
60,
1300
]
],
[
[
1089,
24,
100
],
[
10... | [
[
[
"Ipratropium",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Haloperidol"
]
],
[
[
"Ipratropium",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound... | Ipratropium (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Haloperidol (Compound)
Ipratropium (Compound) causes Dry mouth (Side Effect) and Dry mouth (Side Effect) is caused by Haloperidol (Compound)
Ipratropium may cause a moderate interaction that could exacerbate diseases when taken with Brompheniramin... |
DB11837 | DB13074 | 1,297 | 877 | [
"DDInter1351",
"DDInter1110"
] | Osilodrostat | Macimorelin | Osilodrostat is an inhibitor of 11β-hydroxylase (also referred to as CYP11B1), the enzyme that catalyzes the final step in the biosynthesis of endogenous cortisol. It is used to lower circulating cortisol levels in the treatment of Cushing's disease, a disorder in which cortisol levels are chronically and supraphysiolo... | Macimorelin, a novel and orally active ghrelin mimetic that stimulates GH secretion, is used in the diagnosis of adult GH deficiency (AGHD). More specifically, macimorelin is a peptidomimetic growth hormone secretagogue (GHS) that acts as an agonist of GH secretagogue receptor, or ghrelin receptor (GHS-R1a) to dose-dep... | Major | 2 | [
[
[
1297,
25,
877
]
],
[
[
1297,
62,
112
],
[
112,
23,
877
]
],
[
[
1297,
24,
1320
],
[
1320,
24,
877
]
],
[
[
1297,
64,
651
],
[
651,
... | [
[
[
"Osilodrostat",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Macimorelin"
]
],
[
[
"Osilodrostat",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metr... | Osilodrostat may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Macimorelin
Osilodrostat may cause a moderate interaction that could exacerbate diseases when taken with Elagolix and E... |
DB08860 | DB09054 | 788 | 384 | [
"DDInter1479",
"DDInter905"
] | Pitavastatin | Idelalisib | Pitavastatin, also known as the brand name product Livalo, is a lipid-lowering drug belonging to the statin class of medications. By inhibiting the endogenous production of cholesterol within the liver, statins lower abnormal cholesterol and lipid levels and ultimately reduce the risk of cardiovascular disease. More sp... | Idelalisib is a phosphoinositide 3-kinase inhibitor indicated in the treatment of chronic lymphocytic leukemia (CLL), relapsed follicular B-cell non-Hodgkin lymphoma (FL), and relapsed small lymphocytic lymphoma (SLL). For the treatment of relapsed CLL, it is currently indicated as a second-line agent in combination wi... | Moderate | 1 | [
[
[
788,
24,
384
]
],
[
[
788,
63,
72
],
[
72,
24,
384
]
],
[
[
788,
24,
1468
],
[
1468,
24,
384
]
],
[
[
788,
64,
1668
],
[
1668,
2... | [
[
[
"Pitavastatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Idelalisib"
]
],
[
[
"Pitavastatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Eltrombopag"
],
... | Pitavastatin may cause a moderate interaction that could exacerbate diseases when taken with Eltrombopag and Eltrombopag may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib
Pitavastatin may cause a moderate interaction that could exacerbate diseases when taken with Ponatinib and P... |
DB00563 | DB08860 | 663 | 788 | [
"DDInter1174",
"DDInter1479"
] | Methotrexate | Pitavastatin | Methotrexate is a folate derivative that inhibits several enzymes responsible for nucleotide synthesis. This inhibition leads to suppression of inflammation as well as prevention of cell division. Because of these effects, methotrexate is often used to treat inflammation caused by arthritis or to control cell division ... | Pitavastatin, also known as the brand name product Livalo, is a lipid-lowering drug belonging to the statin class of medications. By inhibiting the endogenous production of cholesterol within the liver, statins lower abnormal cholesterol and lipid levels and ultimately reduce the risk of cardiovascular disease. More sp... | Moderate | 1 | [
[
[
663,
24,
788
]
],
[
[
663,
24,
671
],
[
671,
1,
788
]
],
[
[
663,
24,
700
],
[
700,
40,
788
]
],
[
[
663,
6,
17404
],
[
17404,
4... | [
[
[
"Methotrexate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pitavastatin"
]
],
[
[
"Methotrexate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fluvastatin"
],
... | Methotrexate may cause a moderate interaction that could exacerbate diseases when taken with Fluvastatin and Fluvastatin (Compound) resembles Pitavastatin (Compound)
Methotrexate may cause a moderate interaction that could exacerbate diseases when taken with Atorvastatin and Atorvastatin (Compound) resembles Pitavastat... |
DB00607 | DB01017 | 1,249 | 1,669 | [
"DDInter1256",
"DDInter1224"
] | Nafcillin | Minocycline | A semi-synthetic antibiotic related to penicillin, Naficillin is a narrow-spectrum beta-lactam antibiotic drug. It is a beta-lactamase-resistant penicillin that is indicated for the treatment of Staphylococcal infections caused by strains that are resistant to other penicillins, except those caused by MRSA. It may be u... | Minocycline was first described in the literacture in 1966. It is a second generation tetracycline antibiotic that is active against gram-negative and gram-positive bacteria. Like other semisynthetic tetracyclines, minocycline has modifications to carbons 7-9 on the D ring to generate higher efficacy than previous tetr... | Moderate | 1 | [
[
[
1249,
24,
1669
]
],
[
[
1249,
24,
1572
],
[
1572,
1,
1669
]
],
[
[
1249,
63,
964
],
[
964,
1,
1669
]
],
[
[
1249,
63,
1545
],
[
1545,
... | [
[
[
"Nafcillin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Minocycline"
]
],
[
[
"Nafcillin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Demeclocycline"
],
[... | Nafcillin may cause a moderate interaction that could exacerbate diseases when taken with Demeclocycline and Demeclocycline (Compound) resembles Minocycline (Compound)
Nafcillin may cause a moderate interaction that could exacerbate diseases when taken with Doxycycline and Doxycycline (Compound) resembles Minocycline (... |
DB01095 | DB08881 | 671 | 868 | [
"DDInter769",
"DDInter1925"
] | Fluvastatin | Vemurafenib | Fluvastatin is an antilipemic agent that competitively inhibits hydroxymethylglutaryl-coenzyme A (HMG-CoA) reductase. HMG-CoA reductase catalyzes the conversion of HMG-CoA to mevalonic acid, the rate-limiting step in cholesterol biosynthesis. Fluvastatin belongs to a class of medications called statins and is used to r... | Vemurafenib is a competitive kinase inhibitor with activity against BRAF kinase with mutations like V600E. It exerts its function by binding to the ATP-binding domain of the mutant BRAF. Vemurafenib was co-developed by Roche and Plexxikon and it obtained its FDA approval on August 17, 2011, under the company Hoffmann L... | Moderate | 1 | [
[
[
671,
24,
868
]
],
[
[
671,
6,
8374
],
[
8374,
45,
868
]
],
[
[
671,
7,
3553
],
[
3553,
46,
868
]
],
[
[
671,
18,
1918
],
[
1918,
... | [
[
[
"Fluvastatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vemurafenib"
]
],
[
[
"Fluvastatin",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound... | Fluvastatin (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Vemurafenib (Compound)
Fluvastatin (Compound) upregulates CRIP1 (Gene) and CRIP1 (Gene) is upregulated by Vemurafenib (Compound)
Fluvastatin (Compound) downregulates PCNA (Gene) and PCNA (Gene) is downregulated by Vemurafenib (Compound)
Fluvastati... |
DB00831 | DB01124 | 1,178 | 1,411 | [
"DDInter1866",
"DDInter1828"
] | Trifluoperazine | Tolbutamide | A phenothiazine with actions similar to chlorpromazine. It is used as an antipsychotic and an antiemetic. | Tolbutamide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It is structurally similar to acetohexamide, chlorpropamide and tolazamide and belongs to the sulfonylurea class of insulin secretagogues, which act by stimulating β cells of the pancreas to release... | Moderate | 1 | [
[
[
1178,
24,
1411
]
],
[
[
1178,
24,
959
],
[
959,
40,
1411
]
],
[
[
1178,
63,
245
],
[
245,
40,
1411
]
],
[
[
1178,
18,
2423
],
[
2423,
... | [
[
[
"Trifluoperazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tolbutamide"
]
],
[
[
"Trifluoperazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glipizide"
]... | Trifluoperazine may cause a moderate interaction that could exacerbate diseases when taken with Glipizide and Glipizide (Compound) resembles Tolbutamide (Compound)
Trifluoperazine may cause a moderate interaction that could exacerbate diseases when taken with Glimepiride and Glimepiride (Compound) resembles Tolbutamide... |
DB00488 | DB06372 | 196 | 259 | [
"DDInter57",
"DDInter1594"
] | Altretamine | Rilonacept | An alkylating agent proposed as an antineoplastic. It also acts as a chemosterilant for male houseflies and other insects. | Rilonacept is a dimeric fusion protein consisting of portions of IL-1R and the IL-1R accessory protein linked to the Fc portion of immunoglobulin G1. Rilonacept functions as an interleukin 1 inhibitor and is used in the treatment of CAPS, also known as cryopyrin-associated periodic syndromes, including familial cold au... | Moderate | 1 | [
[
[
196,
24,
259
]
],
[
[
196,
63,
1461
],
[
1461,
23,
259
]
],
[
[
196,
24,
1367
],
[
1367,
63,
259
]
],
[
[
196,
24,
4
],
[
4,
24,... | [
[
[
"Altretamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rilonacept"
]
],
[
[
"Altretamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vitamin E"
],
[
... | Altretamine may cause a moderate interaction that could exacerbate diseases when taken with Vitamin E and Vitamin E may cause a minor interaction that can limit clinical effects when taken with Rilonacept
Altretamine may cause a moderate interaction that could exacerbate diseases when taken with Hepatitis B Vaccine (Re... |
DB00673 | DB09065 | 723 | 760 | [
"DDInter112",
"DDInter424"
] | Aprepitant | Cobicistat | Aprepitant, an antiemetic, is a substance P/neurokinin 1 (NK1) receptor antagonist which, in combination with other antiemetic agents, is indicated for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy. Aprepitant is a selective h... | Cobicistat, marketed under the name Tybost (formerly GS-9350), indicated for treating infection with human immunodeficiency virus (HIV). Although it does not have any anti-HIV activity, cobicistat acts as a pharmacokinetic enhancer by inhibiting cytochrome P450 3A isoforms (CYP3A) and therefore increases the systemic e... | Moderate | 1 | [
[
[
723,
24,
760
]
],
[
[
723,
23,
479
],
[
479,
23,
760
]
],
[
[
723,
62,
1230
],
[
1230,
23,
760
]
],
[
[
723,
23,
907
],
[
907,
6... | [
[
[
"Aprepitant",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cobicistat"
]
],
[
[
"Aprepitant",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Donepezil"
],
[
... | Aprepitant may cause a minor interaction that can limit clinical effects when taken with Donepezil and Donepezil may cause a minor interaction that can limit clinical effects when taken with Cobicistat
Aprepitant may cause a minor interaction that can limit clinical effects when taken with Citalopram and Citalopram may... |
DB00361 | DB01229 | 134 | 973 | [
"DDInter1939",
"DDInter1378"
] | Vinorelbine | Paclitaxel (protein-bound) | Vinorelbine is an anti-mitotic chemotherapy drug that is used in the treatment of several types of malignancies, including breast cancer and non-small cell lung cancer (NSCLC). It was initially approved in the USA in 1990's for the treatment of NSCLC. It is a third-generation vinca alkaloid. The introduction of third-g... | Paclitaxel can cause developmental toxicity, female reproductive toxicity and male reproductive toxicity according to state or federal government labeling requirements. | Moderate | 1 | [
[
[
134,
24,
973
]
],
[
[
134,
24,
310
],
[
310,
63,
973
]
],
[
[
134,
5,
11579
],
[
11579,
44,
973
]
],
[
[
134,
6,
8374
],
[
8374,
... | [
[
[
"Vinorelbine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Paclitaxel"
]
],
[
[
"Vinorelbine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cabazitaxel"
],
[... | Vinorelbine may cause a moderate interaction that could exacerbate diseases when taken with Paclitaxel
Vinorelbine may cause a moderate interaction that could exacerbate diseases when taken with Cabazitaxel and Cabazitaxel may cause a moderate interaction that could exacerbate diseases when taken with Paclitaxel
Vinore... |
DB01168 | DB01209 | 1,053 | 1,359 | [
"DDInter1526",
"DDInter531"
] | Procarbazine | Dezocine | An antineoplastic agent used primarily in combination with mechlorethamine, vincristine, and prednisone (the MOPP protocol) in the treatment of Hodgkin's disease. | Dezocine is a partial opiate drug and is used for pain management. Dezocine is a very effective alternative to fentanyl when administered during outpatient laparoscopy, although is associated with an increased incidence of postoperative nausea. | Major | 2 | [
[
[
1053,
25,
1359
]
],
[
[
1053,
64,
234
],
[
234,
1,
1359
]
],
[
[
1053,
64,
1494
],
[
1494,
24,
1359
]
],
[
[
1053,
63,
13
],
[
13,
... | [
[
[
"Procarbazine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dezocine"
]
],
[
[
"Procarbazine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Pentazocine"
],
[
"Pentazocine",
"{... | Procarbazine may lead to a major life threatening interaction when taken with Pentazocine and Pentazocine (Compound) resembles Dezocine (Compound)
Procarbazine may lead to a major life threatening interaction when taken with Palonosetron and Palonosetron may cause a moderate interaction that could exacerbate diseases w... |
DB01035 | DB01041 | 1,401 | 770 | [
"DDInter1524",
"DDInter1789"
] | Procainamide | Thalidomide | A derivative of procaine with less CNS action. | A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, thalidomide was withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of inflammatory disorders and cancers. Thalidomide displays immunosuppressive and anti-angiogenic activity through modulating ... | Moderate | 1 | [
[
[
1401,
24,
770
]
],
[
[
1401,
21,
29742
],
[
29742,
60,
770
]
],
[
[
1401,
25,
609
],
[
609,
63,
770
]
],
[
[
1401,
64,
1557
],
[
1557,... | [
[
[
"Procainamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Thalidomide"
]
],
[
[
"Procainamide",
"{u} (Compound) causes {v} (Side Effect)",
"Hepatomegaly"
],
[
"Hepatomegaly",
"{u} (Side Effe... | Procainamide (Compound) causes Hepatomegaly (Side Effect) and Hepatomegaly (Side Effect) is caused by Thalidomide (Compound)
Procainamide may lead to a major life threatening interaction when taken with Clarithromycin and Clarithromycin may cause a moderate interaction that could exacerbate diseases when taken with Tha... |
DB10989 | DB11793 | 496 | 738 | [
"DDInter858",
"DDInter1297"
] | Hepatitis A Vaccine | Niraparib | Hepatitis A viral infection can lead to significant morbidity and mortality, with signs and symptoms that include anorexia, nausea, vomiting, and liver failure. Known by several trade names, such as Havrix and Twinrix, the Hepatitis A vaccine has been formulated for immunization against hepatitis A virus (HAV) infectio... | Niraparib is an orally active poly (ADP-ribose) polymerase (PARP) inhibitor. By blocking the enzymes responsible for DNA repair, niraparib induces cytotoxicity in cancer cells. Niraparib is selective towards PARP-1 and PARP-2. First approved by the FDA on March 27, 2017, niraparib is used to treat epithelial ovarian, f... | Moderate | 1 | [
[
[
496,
24,
738
]
],
[
[
496,
63,
1213
],
[
1213,
24,
738
]
],
[
[
496,
24,
1619
],
[
1619,
63,
738
]
],
[
[
496,
24,
351
],
[
351,
... | [
[
[
"Hepatitis A Vaccine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Niraparib"
]
],
[
[
"Hepatitis A Vaccine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dasatinib"... | Hepatitis A Vaccine may cause a moderate interaction that could exacerbate diseases when taken with Dasatinib and Dasatinib may cause a moderate interaction that could exacerbate diseases when taken with Niraparib
Hepatitis A Vaccine may cause a moderate interaction that could exacerbate diseases when taken with Rucapa... |
DB00476 | DB00748 | 109 | 662 | [
"DDInter608",
"DDInter297"
] | Duloxetine | Carbinoxamine | Duloxetine is a dual serotonin and norepinephrine reuptake inhibitor.[label] It was originally discovered in 1993 and developed by Eli Lilly and Company as LY248686. Duloxetine first received approval from the FDA in August, 2004 as Cymbalta for the treatment of Major Depressive Disorder. It has since received approval... | Carbinoxamine is a first generation antihistamine that competes with free histamine for binding at HA-receptor sites. This antagonizes the effects of histamine on HA-receptors, leading to a reduction of the negative symptoms brought on by histamine HA-receptor binding. The product label for carbinoxamine as an over the... | Moderate | 1 | [
[
[
109,
24,
662
]
],
[
[
109,
63,
1594
],
[
1594,
24,
662
]
],
[
[
109,
6,
12523
],
[
12523,
45,
662
]
],
[
[
109,
21,
28921
],
[
28921,
... | [
[
[
"Duloxetine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Carbinoxamine"
]
],
[
[
"Duloxetine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxylamine"
],
[... | Duloxetine may cause a moderate interaction that could exacerbate diseases when taken with Doxylamine and Doxylamine may cause a moderate interaction that could exacerbate diseases when taken with Carbinoxamine
Duloxetine (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Carbinoxamine (Compound)
Duloxetine (... |
DB01255 | DB09104 | 633 | 286 | [
"DDInter1078",
"DDInter1118"
] | Lisdexamfetamine | Magnesium hydroxide | Lisdexamfetamine is a prodrug of [dextroamphetamine], a central nervous system stimulant known as d-amphetamine, covalently attached to the naturally occurring amino acid L-lysine. Lisdexamfetamine is the first chemically formulated prodrug stimulant and was first approved by the FDA in April 2008. It was also approved... | Magnesium hydroxide is an inorganic compound. It is naturally found as the mineral brucite. Magnesium hydroxide can be used as an antacid or a laxative in either an oral liquid suspension or chewable tablet form. Additionally, magnesium hydroxide has smoke suppressing and flame retardant properties and is thus used com... | Moderate | 1 | [
[
[
633,
24,
286
]
],
[
[
633,
63,
820
],
[
820,
23,
286
]
],
[
[
633,
40,
743
],
[
743,
23,
286
]
],
[
[
633,
1,
1523
],
[
1523,
23... | [
[
[
"Lisdexamfetamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium hydroxide"
]
],
[
[
"Lisdexamfetamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alimem... | Lisdexamfetamine may cause a moderate interaction that could exacerbate diseases when taken with Alimemazine and Alimemazine may cause a minor interaction that can limit clinical effects when taken with Magnesium hydroxide
Lisdexamfetamine (Compound) resembles Lisinopril (Compound) and Lisinopril may cause a minor inte... |
DB06372 | DB06674 | 259 | 908 | [
"DDInter1594",
"DDInter837"
] | Rilonacept | Golimumab | Rilonacept is a dimeric fusion protein consisting of portions of IL-1R and the IL-1R accessory protein linked to the Fc portion of immunoglobulin G1. Rilonacept functions as an interleukin 1 inhibitor and is used in the treatment of CAPS, also known as cryopyrin-associated periodic syndromes, including familial cold au... | Golimumab is a human IgG1қ monoclonal antibody derived from immunizing genetically engineered mice with human TNFα. Golimumab binds and inhibits soluble and transmembrane human TNFα. Increased TNFα is associated with chronic inflammation. Thus golimumab is indicated for use in adults (i) as an adjunct to methotrexate t... | Major | 2 | [
[
[
259,
25,
908
]
],
[
[
259,
23,
1193
],
[
1193,
62,
908
]
],
[
[
259,
62,
1461
],
[
1461,
23,
908
]
],
[
[
259,
63,
336
],
[
336,
... | [
[
[
"Rilonacept",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Golimumab"
]
],
[
[
"Rilonacept",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Zinc gluconate"
],
[
"Zinc gluc... | Rilonacept may cause a minor interaction that can limit clinical effects when taken with Zinc gluconate and Zinc gluconate may cause a minor interaction that can limit clinical effects when taken with Golimumab
Rilonacept may cause a minor interaction that can limit clinical effects when taken with Vitamin E and Vitami... |
DB00705 | DB00857 | 441 | 1,387 | [
"DDInter496",
"DDInter1768"
] | Delavirdine | Terbinafine | A potent, non-nucleoside reverse transcriptase inhibitor with activity specific for HIV-1. | Terbinafine hydrochloride (Lamisil) is a synthetic allylamine antifungal.[L9065,L9068] It is highly lipophilic in nature and tends to accumulate in skin, nails, and fatty tissues. Like other allylamines, terbinafine inhibits ergosterol synthesis by inhibiting the fungal squalene monooxygenase (also called squalene epox... | Moderate | 1 | [
[
[
441,
24,
1387
]
],
[
[
441,
6,
8374
],
[
8374,
45,
1387
]
],
[
[
441,
21,
28822
],
[
28822,
60,
1387
]
],
[
[
441,
63,
168
],
[
168,
... | [
[
[
"Delavirdine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Terbinafine"
]
],
[
[
"Delavirdine",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound... | Delavirdine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Terbinafine (Compound)
Delavirdine (Compound) causes Alopecia (Side Effect) and Alopecia (Side Effect) is caused by Terbinafine (Compound)
Delavirdine may cause a moderate interaction that could exacerbate diseases when taken with Bortezomib and B... |
DB01087 | DB08904 | 1,520 | 375 | [
"DDInter1520",
"DDInter342"
] | Primaquine | Certolizumab pegol | An aminoquinoline that is given by mouth to produce a radical cure and prevent relapse of vivax and ovale malarias following treatment with a blood schizontocide. It has also been used to prevent transmission of falciparum malaria by those returning to areas where there is a potential for re-introduction of malaria. Ad... | Certolizumab pegol is a pegylated monoclonal antibody against the tumor necrosis factor-alpha (TNF-alpha). It is formed with a humanized Fab fragment of 50 kDa, from an IgG 1 isotype, fused to a 40 kDa polyethylene glycol moiety replacing the Fc antibody region. The absence of the Fc region was ideated to prevent compl... | Major | 2 | [
[
[
1520,
25,
375
]
],
[
[
1520,
25,
1593
],
[
1593,
24,
375
]
],
[
[
1520,
64,
1112
],
[
1112,
24,
375
]
],
[
[
1520,
25,
1328
],
[
1328,... | [
[
[
"Primaquine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Certolizumab pegol"
]
],
[
[
"Primaquine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Crizotinib"
],
[
"Crizotinib",
... | Primaquine may lead to a major life threatening interaction when taken with Crizotinib and Crizotinib may cause a moderate interaction that could exacerbate diseases when taken with Certolizumab pegol
Primaquine may lead to a major life threatening interaction when taken with Auranofin and Auranofin may cause a moderat... |
DB00635 | DB09035 | 1,573 | 410 | [
"DDInter1515",
"DDInter1308"
] | Prednisone | Nivolumab | A synthetic anti-inflammatory glucocorticoid derived from [cortisone]. It is biologically inert and converted to [prednisolone] in the liver. Prednisone was granted FDA approval on 21 February 1955. | Nivolumab is a fully human IgG4 antibody targeting the immune checkpoint programmed death receptor-1 (PD-1). This antibody was produced entirely in mice and grafted onto human kappa and IgG4 Fc region with the mutation _S228P_ for additional stability and reduced variability. It was developed by Bristol Myers Squibb. N... | Moderate | 1 | [
[
[
1573,
24,
410
]
],
[
[
1573,
1,
175
],
[
175,
24,
410
]
],
[
[
1573,
40,
251
],
[
251,
24,
410
]
],
[
[
1573,
24,
384
],
[
384,
... | [
[
[
"Prednisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nivolumab"
]
],
[
[
"Prednisone",
"{u} (Compound) resembles {v} (Compound)",
"Triamcinolone"
],
[
"Triamcinolone",
"{u} may cause a mo... | Prednisone (Compound) resembles Triamcinolone (Compound) and Triamcinolone may cause a moderate interaction that could exacerbate diseases when taken with Nivolumab
Prednisone (Compound) resembles Betamethasone (Compound) and Betamethasone may cause a moderate interaction that could exacerbate diseases when taken with ... |
DB00668 | DB01124 | 874 | 1,411 | [
"DDInter652",
"DDInter1828"
] | Epinephrine | Tolbutamide | Epinephrine, also known as _adrenaline_, is a hormone and neurotransmitter and produced by the adrenal glands that can also be used as a drug due to its various important functions. Though it has long been used in the treatment of hypersensitivity reactions, epinephrine in the auto-injector form (EpiPen) has been avail... | Tolbutamide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It is structurally similar to acetohexamide, chlorpropamide and tolazamide and belongs to the sulfonylurea class of insulin secretagogues, which act by stimulating β cells of the pancreas to release... | Moderate | 1 | [
[
[
874,
24,
1411
]
],
[
[
874,
24,
959
],
[
959,
40,
1411
]
],
[
[
874,
63,
245
],
[
245,
40,
1411
]
],
[
[
874,
6,
6017
],
[
6017,
... | [
[
[
"Epinephrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tolbutamide"
]
],
[
[
"Epinephrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glipizide"
],
[
... | Epinephrine may cause a moderate interaction that could exacerbate diseases when taken with Glipizide and Glipizide (Compound) resembles Tolbutamide (Compound)
Epinephrine may cause a moderate interaction that could exacerbate diseases when taken with Glimepiride and Glimepiride (Compound) resembles Tolbutamide (Compou... |
DB00047 | DB15093 | 176 | 1,654 | [
"DDInter932",
"DDInter1698"
] | Insulin glargine | Somapacitan | Insulin glargine is a long-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes. Insulin is typically prescribed for the management of diabetes mellitus to mimic the activity of endogenously produced human insulin, a peptide hormone produced by beta cells of the pancreas t... | Somapacitan, also known as NNC0195-0092, is a growth hormone analog indicated to treat adults with growth hormone deficiency.[A219126,L15661] This human growth hormone analog differs by the creation of an albumin binding site, and prolonging the effect so that it requires weekly dosing rather than daily. Somapacitan wa... | Moderate | 1 | [
[
[
176,
24,
1654
]
],
[
[
176,
24,
168
],
[
168,
23,
1654
]
],
[
[
176,
24,
433
],
[
433,
24,
1654
]
],
[
[
176,
24,
1101
],
[
1101,
... | [
[
[
"Insulin glargine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Somapacitan"
]
],
[
[
"Insulin glargine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bortezomib"
... | Insulin glargine may cause a moderate interaction that could exacerbate diseases when taken with Bortezomib and Bortezomib may cause a minor interaction that can limit clinical effects when taken with Somapacitan
Insulin glargine may cause a moderate interaction that could exacerbate diseases when taken with Ertugliflo... |
DB01006 | DB11652 | 300 | 1,155 | [
"DDInter1040",
"DDInter1891"
] | Letrozole | Tucatinib | Letrozole, or CGS 20267, is an oral non-steroidal type II aromatase inhibitor first described in the literature in 1990.[A190543,A1559,L11623,L11626] It is a third generation aromatase inhibitor like [exemestane] and [anastrozole], meaning it does not significantly affect cortisol, aldosterone, and thyroxine. Letrozole... | Tucatinib is a kinase inhibitor drug used with [trastuzumab] and [capecitabine] in the treatment of unresectable or metastatic HER-2 positive breast cancer. It was developed by Seattle Genetics and approved by the FDA on April 17, 2020. Tucatinib is a promising new treatment for patients with metastatic breast cancer w... | Moderate | 1 | [
[
[
300,
24,
1155
]
],
[
[
300,
63,
1101
],
[
1101,
23,
1155
]
],
[
[
300,
24,
214
],
[
214,
63,
1155
]
],
[
[
300,
63,
723
],
[
723,
... | [
[
[
"Letrozole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tucatinib"
]
],
[
[
"Letrozole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bexarotene"
],
[
... | Letrozole may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene and Bexarotene may cause a minor interaction that can limit clinical effects when taken with Tucatinib
Letrozole may cause a moderate interaction that could exacerbate diseases when taken with Fostamatinib and Fostamati... |
DB00041 | DB00206 | 1,648 | 1,245 | [
"DDInter38",
"DDInter1582"
] | Aldesleukin | Reserpine | Aldesleukin, a lymphokine, is produced by recombinant DNA technology using a genetically engineered E. coli strain containing an analog of the human interleukin-2 gene. Genetic engineering techniques were used to modify the human IL-2 gene, and the resulting expression clone encodes a modified human interleukin-2. This... | An alkaloid found in the roots of Rauwolfia serpentina and R. vomitoria. Reserpine inhibits the uptake of norepinephrine into storage vesicles resulting in depletion of catecholamines and serotonin from central and peripheral axon terminals. It has been used as an antihypertensive and an antipsychotic as well as a rese... | Moderate | 1 | [
[
[
1648,
24,
1245
]
],
[
[
1648,
24,
1340
],
[
1340,
1,
1245
]
],
[
[
1648,
25,
1064
],
[
1064,
63,
1245
]
],
[
[
1648,
24,
401
],
[
401,... | [
[
[
"Aldesleukin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Reserpine"
]
],
[
[
"Aldesleukin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Deserpidine"
],
[
... | Aldesleukin may cause a moderate interaction that could exacerbate diseases when taken with Deserpidine and Deserpidine (Compound) resembles Reserpine (Compound)
Aldesleukin may lead to a major life threatening interaction when taken with Cladribine and Cladribine may cause a moderate interaction that could exacerbate ... |
DB00224 | DB11828 | 215 | 1,406 | [
"DDInter917",
"DDInter1281"
] | Indinavir | Neratinib | A potent and specific HIV protease inhibitor that appears to have good oral bioavailability. [PubChem] | Neratinib was approved in July 2017 for use as an extended adjuvant therapy in Human Epidermal Growth Factor Receptor 2 (HER2) positive breast cancer. Approval was granted to Puma Biotechnology Inc. for the tradename Nerlynx. Neratinib is currently under investigation for use in many other forms of cancer. | Major | 2 | [
[
[
215,
25,
1406
]
],
[
[
215,
25,
1135
],
[
1135,
23,
1406
]
],
[
[
215,
25,
392
],
[
392,
24,
1406
]
],
[
[
215,
24,
1195
],
[
1195,
... | [
[
[
"Indinavir",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Neratinib"
]
],
[
[
"Indinavir",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Naloxegol"
],
[
"Naloxegol",
"{u} may ca... | Indinavir may lead to a major life threatening interaction when taken with Naloxegol and Naloxegol may cause a minor interaction that can limit clinical effects when taken with Neratinib
Indinavir may lead to a major life threatening interaction when taken with Lapatinib and Lapatinib may cause a moderate interaction t... |
DB08870 | DB14444 | 850 | 151 | [
"DDInter228",
"DDInter924"
] | Brentuximab vedotin | Influenza A virus A/California/7/2009 (H1N1)-like antigen (propiolactone inactivated) | Brentuximab vedotin, also known as Adcetris®, is an antibody-drug conjugate that combines an anti-CD30 antibody with the drug monomethyl auristatin E (MMAE). It is an anti-neoplastic agent used in the treatment of Hodgkin's lymphoma and systemic anaplastic large-cell lymphoma. Brentuximab vedotin was initially approved... | A seasonally-specific component of the influenza vaccine. The influenza vaccine, also known as the "flu shot", is a vaccine that protects against infection from the influenza viruses. Vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which stimulates an immuno... | Moderate | 1 | [
[
[
850,
24,
151
]
],
[
[
850,
63,
66
],
[
66,
24,
151
]
],
[
[
850,
24,
36
],
[
36,
24,
151
]
],
[
[
850,
25,
375
],
[
375,
24,
... | [
[
[
"Brentuximab vedotin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Influenza A virus A/California/7/2009 (H1N1)-like antigen (propiolactone inactivated)"
]
],
[
[
"Brentuximab vedotin",
"{u} may cause a moderate intera... | Brentuximab vedotin may cause a moderate interaction that could exacerbate diseases when taken with Efalizumab and Efalizumab may cause a moderate interaction that could exacerbate diseases when taken with Influenza A virus A/California/7/2009 (H1N1)-like antigen (propiolactone inactivated)
Brentuximab vedotin may caus... |
DB00261 | DB01246 | 702 | 820 | [
"DDInter93",
"DDInter45"
] | Anagrelide | Alimemazine | Anagrelide is a platelet-reducing agent used to lower dangerously elevated platelet levels (i.e. to treat thrombocythemia) in patients with myeloproliferative neoplasms. It is an oral imidazoquinazoline that was first approved for use in the US in 1997. It appears to carry a better response rate than other thrombocythe... | A phenothiazine derivative that is used as an antipruritic. | Major | 2 | [
[
[
702,
25,
820
]
],
[
[
702,
25,
401
],
[
401,
24,
820
]
],
[
[
702,
24,
1236
],
[
1236,
24,
820
]
],
[
[
702,
25,
675
],
[
675,
2... | [
[
[
"Anagrelide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Alimemazine"
]
],
[
[
"Anagrelide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Promethazine"
],
[
"Promethazine",
"... | Anagrelide may lead to a major life threatening interaction when taken with Promethazine and Promethazine may cause a moderate interaction that could exacerbate diseases when taken with Alimemazine
Anagrelide may cause a moderate interaction that could exacerbate diseases when taken with Carbamazepine and Carbamazepine... |
DB00736 | DB01232 | 660 | 1,327 | [
"DDInter676",
"DDInter1640"
] | Esomeprazole | Saquinavir | Esomeprazole, sold under the brand name Nexium, is a proton pump inhibitor (PPI) medication used for the management of gastroesophageal reflux disease (GERD), for gastric protection to prevent recurrence of stomach ulcers or gastric damage from chronic use of NSAIDs, and for the treatment of pathological hypersecretory... | Saquinavir is an HIV-1 protease inhibitor used in combination with [ritonavir] and other antiretrovirals for the treatment of human immunodeficiency virus-1 (HIV-1) infection. In 1995 it became the first protease inhibitor approved by the FDA, followed shortly by ritonavir in 1996, and remains in clinical use today due... | Moderate | 1 | [
[
[
660,
24,
1327
]
],
[
[
660,
64,
798
],
[
798,
40,
1327
]
],
[
[
660,
25,
915
],
[
915,
40,
1327
]
],
[
[
660,
63,
215
],
[
215,
... | [
[
[
"Esomeprazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Saquinavir"
]
],
[
[
"Esomeprazole",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Nelfinavir"
],
[
"Nelfin... | Esomeprazole may lead to a major life threatening interaction when taken with Nelfinavir and Nelfinavir (Compound) resembles Saquinavir (Compound)
Esomeprazole may lead to a major life threatening interaction when taken with Atazanavir and Atazanavir (Compound) resembles Saquinavir (Compound)
Esomeprazole may cause a m... |
DB00065 | DB11988 | 581 | 270 | [
"DDInter923",
"DDInter1321"
] | Infliximab | Ocrelizumab | Infliximab is a tumor necrosis factor (TNF-alpha or TNF-α) blocker and a chimeric monoclonal IgG1 antibody composed of human constant (75%) and murine variable (25%) regions. Infliximab is produced by a recombinant cell line cultured by continuous perfusion. Tumor necrosis factor-alpha (TNF-α) is a key proinflammatory ... | Ocrelizumab is a CD20-directed cytolytic antibody indicated for the treatment of patients with primary progressive or relapsing forms of multiple sclerosis (MS). It is a second-generation recombinant humanized monoclonal IgG1 antibody that selectively targets B-cells that express the CD20 antigen. Compared to non-human... | Major | 2 | [
[
[
581,
25,
270
]
],
[
[
581,
23,
1193
],
[
1193,
23,
270
]
],
[
[
581,
25,
1060
],
[
1060,
63,
270
]
],
[
[
581,
25,
134
],
[
134,
... | [
[
[
"Infliximab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ocrelizumab"
]
],
[
[
"Infliximab",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Zinc gluconate"
],
[
"Zinc gl... | Infliximab may cause a minor interaction that can limit clinical effects when taken with Zinc gluconate and Zinc gluconate may cause a minor interaction that can limit clinical effects when taken with Ocrelizumab
Infliximab may lead to a major life threatening interaction when taken with Enfortumab vedotin and Enfortum... |
DB00295 | DB00477 | 475 | 216 | [
"DDInter1244",
"DDInter363"
] | Morphine | Chlorpromazine | Morphine, the main alkaloid of opium, was first obtained from poppy seeds in 1805. It is a potent analgesic, though its use is limited due to tolerance, withdrawal, and the risk of abuse. Morphine is still routinely used today, though there are a number of semi-synthetic opioids of varying strength such as [codeine], [... | The prototypical phenothiazine antipsychotic drug. Like the other drugs in this class, chlorpromazine's antipsychotic actions are thought to be due to long-term adaptation by the brain to blocking dopamine receptors. Chlorpromazine has several other actions and therapeutic uses, including as an antiemetic and in the tr... | Major | 2 | [
[
[
475,
25,
216
]
],
[
[
475,
25,
1178
],
[
1178,
1,
216
]
],
[
[
475,
25,
902
],
[
902,
40,
216
]
],
[
[
475,
24,
662
],
[
662,
63... | [
[
[
"Morphine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Chlorpromazine"
]
],
[
[
"Morphine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Trifluoperazine"
],
[
"Trifluoperazine",
... | Morphine may lead to a major life threatening interaction when taken with Trifluoperazine and Trifluoperazine (Compound) resembles Chlorpromazine (Compound)
Morphine may lead to a major life threatening interaction when taken with Clobazam and Clobazam (Compound) resembles Chlorpromazine (Compound)
Morphine may cause a... |
DB01233 | DB04837 | 1,311 | 649 | [
"DDInter1197",
"DDInter407"
] | Metoclopramide | Clofedanol | Diabetic gastroparesis is a condition that causes frequent nausea and vomiting, which has a negative impact on quality of life and poses a significant burden on the healthcare system. Metoclopramide is a dopamine antagonist used to treat nausea and vomiting that may be associated with diabetic gastroparesis in addition... | Clofedanol is a centrally-acting cough suppressant available in Canada under the trade name Ulone. It is not available in the United States. | Moderate | 1 | [
[
[
1311,
24,
649
]
],
[
[
1311,
63,
1376
],
[
1376,
24,
649
]
],
[
[
1311,
64,
675
],
[
675,
40,
649
]
],
[
[
1311,
63,
1301
],
[
1301,
... | [
[
[
"Metoclopramide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clofedanol"
]
],
[
[
"Metoclopramide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diphenhydramine"
... | Metoclopramide may cause a moderate interaction that could exacerbate diseases when taken with Diphenhydramine and Diphenhydramine may cause a moderate interaction that could exacerbate diseases when taken with Clofedanol
Metoclopramide may lead to a major life threatening interaction when taken with Dextropropoxyphene... |
DB00214 | DB09080 | 1,028 | 144 | [
"DDInter1836",
"DDInter1331"
] | Torasemide | Olodaterol | Torasemide is a high-ceiling loop diuretic. Structurally, it is a pyridine-sulfonylurea used as an antihypertensive agent. Torasemide was first approved for clinical use by the FDA in 1993. | Olodaterol is a novel, long-acting beta2-adrenergic agonist (LABA) that exerts its pharmacological effect by binding and activating beta2-adrenergic receptors located primarily in the lungs. Beta2-adrenergic receptors are membrane-bound receptors that are normally activated by endogenous epinephrine whose signalling, v... | Moderate | 1 | [
[
[
1028,
24,
144
]
],
[
[
1028,
24,
11
],
[
11,
24,
144
]
],
[
[
1028,
25,
57
],
[
57,
24,
144
]
],
[
[
1028,
63,
1324
],
[
1324,
2... | [
[
[
"Torasemide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Olodaterol"
]
],
[
[
"Torasemide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Toremifene"
],
[
... | Torasemide may cause a moderate interaction that could exacerbate diseases when taken with Toremifene and Toremifene may cause a moderate interaction that could exacerbate diseases when taken with Olodaterol
Torasemide may lead to a major life threatening interaction when taken with Arsenic trioxide and Arsenic trioxid... |
DB00438 | DB00787 | 149 | 387 | [
"DDInter330",
"DDInter25"
] | Ceftazidime | Acyclovir | Bacteria possess a cell wall comprising a glycopeptide polymer commonly known as peptidoglycan, which is synthesized and remodelled through the action of a family of enzymes known as "penicillin-binding proteins" (PBPs). β-lactam antibiotics, including cephalosporins, are PBP inhibitors that, through inhibition of esse... | Acyclovir is a nucleotide analog antiviral used to treat herpes simplex, _Varicella zoster_, herpes zoster, herpes labialis, and acute herpetic keratitis[L7303,L7315,L7318,L7321,L7324,L7327]. Acyclovir is generally used first line in the treatment of these viruses and some products are indicated for patients as young a... | Moderate | 1 | [
[
[
149,
24,
387
]
],
[
[
149,
6,
10612
],
[
10612,
45,
387
]
],
[
[
149,
21,
29547
],
[
29547,
60,
387
]
],
[
[
149,
24,
1096
],
[
1096,
... | [
[
[
"Ceftazidime",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Acyclovir"
]
],
[
[
"Ceftazidime",
"{u} (Compound) binds {v} (Gene)",
"SLC22A6"
],
[
"SLC22A6",
"{u} (Gene) is bound by {v} (Compound... | Ceftazidime (Compound) binds SLC22A6 (Gene) and SLC22A6 (Gene) is bound by Acyclovir (Compound)
Ceftazidime (Compound) causes Skin exfoliation (Side Effect) and Skin exfoliation (Side Effect) is caused by Acyclovir (Compound)
Ceftazidime may cause a moderate interaction that could exacerbate diseases when taken with My... |
DB00877 | DB11901 | 629 | 913 | [
"DDInter1678",
"DDInter107"
] | Sirolimus | Apalutamide | Sirolimus, also known as rapamycin, is a macrocyclic lactone antibiotic produced by bacteria _Streptomyces hygroscopicus_, which was isolated from the soil of the Vai Atari region of Rapa Nui (Easter Island). It was first isolated and identified as an antifungal agent with potent anticandida activity; however, after it... | Apalutamide is a potent androgen receptor (AR) antagonist that selectively binds to the ligand-binding domain of AR and blocks AR nuclear translocation or binding to androgen response elements . It has been used in trials studying the treatment of Prostate Cancer, Hepatic Impairment, Prostatic Neoplasms, Castration-Res... | Major | 2 | [
[
[
629,
25,
913
]
],
[
[
629,
63,
312
],
[
312,
23,
913
]
],
[
[
629,
63,
1322
],
[
1322,
24,
913
]
],
[
[
629,
64,
600
],
[
600,
2... | [
[
[
"Sirolimus",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Apalutamide"
]
],
[
[
"Sirolimus",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Eplerenone"
],
[
"Eplerenone"... | Sirolimus may cause a moderate interaction that could exacerbate diseases when taken with Eplerenone and Eplerenone may cause a minor interaction that can limit clinical effects when taken with Apalutamide
Sirolimus may cause a moderate interaction that could exacerbate diseases when taken with Alfentanil and Alfentani... |
DB00712 | DB11817 | 1,274 | 1,259 | [
"DDInter763",
"DDInter165"
] | Flurbiprofen | Baricitinib | Flurbiprofen, a propionic acid derivative, is a nonsteroidal anti-inflammatory agent (NSAIA) with antipyretic and analgesic activity. Oral formulations of flurbiprofen may be used for the symptomatic treatment of rheumatoid arthritis, osteoarthritis and anklylosing spondylitis. Flurbiprofen may also be used topically p... | Baricitinib is a Janus kinase (JAK) inhibitor. JAKs are tyrosine protein kinases that play an important role in pro-inflammatory signaling pathways. Overactive JAKs have been implicated in autoimmune disorders, such as rheumatoid arthritis. By inhibiting the actions of JAK1 and JAK2, baricitinib attenuates JAK-mediated... | Moderate | 1 | [
[
[
1274,
24,
1259
]
],
[
[
1274,
63,
598
],
[
598,
24,
1259
]
],
[
[
1274,
24,
935
],
[
935,
24,
1259
]
],
[
[
1274,
35,
914
],
[
914,
... | [
[
[
"Flurbiprofen",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Baricitinib"
]
],
[
[
"Flurbiprofen",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nabumetone"
],
... | Flurbiprofen may cause a moderate interaction that could exacerbate diseases when taken with Nabumetone and Nabumetone may cause a moderate interaction that could exacerbate diseases when taken with Baricitinib
Flurbiprofen may cause a moderate interaction that could exacerbate diseases when taken with Ketoprofen and K... |
DB11581 | DB12267 | 1,456 | 1,476 | [
"DDInter1926",
"DDInter233"
] | Venetoclax | Brigatinib | Venetoclax is a BCL-2 inhibitor that was initially approved by the FDA in April 2016 [FDA label]. Proteins in the B cell CLL/lymphoma 2 (BCL-2) family are important regulators of the apoptotic (programmed cell death) process,. Venetoclax is used to treat chronic lymphocytic leukemia (CLL) and certain types of small lym... | Brigatinib, originally named AP26113, is a reversible dual inhibitor of anaplastic lymphoma kinase (ALK) and epidermal growth factor receptor (EGFR). It presents selectivity against the mutant forms of EGFR compared to the wild-type. It also exhibits selectivity against 9 different Crizotinib-resistant mutants of the E... | Moderate | 1 | [
[
[
1456,
24,
1476
]
],
[
[
1456,
24,
1612
],
[
1612,
23,
1476
]
],
[
[
1456,
62,
1135
],
[
1135,
23,
1476
]
],
[
[
1456,
63,
629
],
[
629... | [
[
[
"Venetoclax",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brigatinib"
]
],
[
[
"Venetoclax",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fostemsavir"
],
[
... | Venetoclax may cause a moderate interaction that could exacerbate diseases when taken with Fostemsavir and Fostemsavir may cause a minor interaction that can limit clinical effects when taken with Brigatinib
Venetoclax may cause a minor interaction that can limit clinical effects when taken with Naloxegol and Naloxegol... |
DB00903 | DB12865 | 1,680 | 922 | [
"DDInter686",
"DDInter688"
] | Etacrynic acid | Etelcalcetide | A compound that inhibits symport of sodium, potassium, and chloride primarily in the ascending limb of Henle, but also in the proximal and distal tubules. This pharmacological action results in excretion of these ions, increased urinary output, and reduction in extracellular fluid. This compound has been classified as ... | Etelcalcetide is a calcimimetic drug for the treatment of secondary hyperparathyroidism in patients undergoing hemodialysis. Etelcalcetide was approved (trade name Parsabiv) for the treatment of secondary hyperparathyroidism (HPT) in adult patients with chronic kidney disease (CKD) on hemodialysis in February, 2017. | Major | 2 | [
[
[
1680,
25,
922
]
],
[
[
1680,
63,
589
],
[
589,
25,
922
]
],
[
[
1680,
24,
923
],
[
923,
25,
922
]
],
[
[
1680,
63,
589
],
[
589,
... | [
[
[
"Etacrynic acid",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Etelcalcetide"
]
],
[
[
"Etacrynic acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cisplatin"
],
[
"... | Etacrynic acid may cause a moderate interaction that could exacerbate diseases when taken with Cisplatin and Cisplatin may lead to a major life threatening interaction when taken with Etelcalcetide
Etacrynic acid may cause a moderate interaction that could exacerbate diseases when taken with Amifostine and Amifostine m... |
DB06650 | DB14409 | 1,500 | 1,129 | [
"DDInter1324",
"DDInter867"
] | Ofatumumab | Human adenovirus e serotype 4 strain cl-68578 antigen | Ofatumumab is a novel anti-CD20 monoclonal antibody that targets B-cells. It is an IgG1κ human monoclonal antibody produced from a recombinant murine cell line (NS0) via transgenic mouse and hybridoma technology. Ofatumumab works by recognizing antigens that are expressed on the tumour cells in certain cancers; however... | Human adenovirus e serotype 4 strain cl-68578 antigen is a vaccine. | Moderate | 1 | [
[
[
1500,
24,
1129
]
],
[
[
1500,
64,
1057
],
[
1057,
24,
1129
]
],
[
[
1500,
63,
1683
],
[
1683,
24,
1129
]
],
[
[
1500,
24,
738
],
[
738... | [
[
[
"Ofatumumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Human adenovirus e serotype 4 strain cl-68578 antigen"
]
],
[
[
"Ofatumumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
... | Ofatumumab may lead to a major life threatening interaction when taken with Etanercept and Etanercept may cause a moderate interaction that could exacerbate diseases when taken with Human adenovirus e serotype 4 strain cl-68578 antigen
Ofatumumab may cause a moderate interaction that could exacerbate diseases when take... |
DB08904 | DB11989 | 375 | 1,434 | [
"DDInter342",
"DDInter183"
] | Certolizumab pegol | Benznidazole | Certolizumab pegol is a pegylated monoclonal antibody against the tumor necrosis factor-alpha (TNF-alpha). It is formed with a humanized Fab fragment of 50 kDa, from an IgG 1 isotype, fused to a 40 kDa polyethylene glycol moiety replacing the Fc antibody region. The absence of the Fc region was ideated to prevent compl... | Benznidazole was granted accelerated approval for the treatment of Chagas disease in children 2-12 years of age by the FDA on August 29, 2017. It is the first treatment made available in the United States for Chagas disease. | Moderate | 1 | [
[
[
375,
24,
1434
]
],
[
[
375,
63,
788
],
[
788,
24,
1434
]
],
[
[
375,
64,
309
],
[
309,
24,
1434
]
],
[
[
375,
24,
148
],
[
148,
... | [
[
[
"Certolizumab pegol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Benznidazole"
]
],
[
[
"Certolizumab pegol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pitavasta... | Certolizumab pegol may cause a moderate interaction that could exacerbate diseases when taken with Pitavastatin and Pitavastatin may cause a moderate interaction that could exacerbate diseases when taken with Benznidazole
Certolizumab pegol may lead to a major life threatening interaction when taken with Ixabepilone an... |
DB00584 | DB01088 | 610 | 714 | [
"DDInter638",
"DDInter908"
] | Enalapril | Iloprost | Enalapril is a prodrug belonging to the angiotensin-converting enzyme (ACE) inhibitor drug class that works on the renin-angiotensin-aldosterone system, which is responsible for the regulation of blood pressure and fluid and electrolyte homeostasis. Enalapril is an orally-active and long-acting nonsulphydryl antihypert... | Iloprost is a mimetic of prostacyclin (PGI2; epoprostenol). Iloprost consists of a mixture of the 4R and 4S diastereoisomers at a ratio of approximately 53:47. It is a potent vasodilator with reported anti-thrombotic properties. | Moderate | 1 | [
[
[
610,
24,
714
]
],
[
[
610,
40,
1638
],
[
1638,
24,
714
]
],
[
[
610,
24,
1479
],
[
1479,
24,
714
]
],
[
[
610,
63,
1648
],
[
1648,
... | [
[
[
"Enalapril",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Iloprost"
]
],
[
[
"Enalapril",
"{u} (Compound) resembles {v} (Compound)",
"Trandolapril"
],
[
"Trandolapril",
"{u} may cause a moderat... | Enalapril (Compound) resembles Trandolapril (Compound) and Trandolapril may cause a moderate interaction that could exacerbate diseases when taken with Iloprost
Enalapril may cause a moderate interaction that could exacerbate diseases when taken with Acetylsalicylic acid and Acetylsalicylic acid may cause a moderate in... |
DB00446 | DB00783 | 597 | 1,438 | [
"DDInter351",
"DDInter679"
] | Chloramphenicol | Estradiol | An antibiotic first isolated from cultures of _Streptomyces venezuelae_ in 1947 but now produced synthetically. It has a relatively simple structure and was the first broad-spectrum antibiotic to be discovered. It acts by interfering with bacterial protein synthesis and is mainly bacteriostatic. (From Martindale, The E... | Estradiol is a naturally occurring hormone circulating endogenously in females. It is commercially available in several hormone therapy products for managing conditions associated with reduced estrogen, such as vulvovaginal atrophy and hot flashes. Some available forms of estradiol include oral tablets, injections, vag... | Moderate | 1 | [
[
[
597,
24,
1438
]
],
[
[
597,
24,
890
],
[
890,
40,
1438
]
],
[
[
597,
6,
8374
],
[
8374,
45,
1438
]
],
[
[
597,
7,
2329
],
[
2329,
... | [
[
[
"Chloramphenicol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Estradiol"
]
],
[
[
"Chloramphenicol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mestranol"
],
... | Chloramphenicol may cause a moderate interaction that could exacerbate diseases when taken with Mestranol and Mestranol (Compound) resembles Estradiol (Compound)
Chloramphenicol (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Estradiol (Compound)
Chloramphenicol (Compound) upregulates UBE2L6 (Gene) and UBE... |
DB00524 | DB06292 | 811 | 549 | [
"DDInter1199",
"DDInter474"
] | Metolazone | Dapagliflozin | A quinazoline-sulfonamide that is considered a thiazide-like diuretic which is long-acting so useful in chronic renal failure. It also tends to lower blood pressure and increase potassium loss. | Dapagliflozin is a sodium-glucose cotransporter 2 (SGLT2) inhibitor, and it was the first SLGT2 inhibitor to be approved. indicated for managing diabetes mellitus type 2. When combined with diet and exercise in adults, dapagliflozin helps to improve glycemic control by inhibiting glucose reabsorption in the proximal tu... | Moderate | 1 | [
[
[
811,
24,
549
]
],
[
[
811,
24,
1344
],
[
1344,
40,
549
]
],
[
[
811,
21,
28898
],
[
28898,
60,
549
]
],
[
[
811,
63,
1179
],
[
1179,
... | [
[
[
"Metolazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dapagliflozin"
]
],
[
[
"Metolazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Canagliflozin"
],
... | Metolazone may cause a moderate interaction that could exacerbate diseases when taken with Canagliflozin and Canagliflozin (Compound) resembles Dapagliflozin (Compound)
Metolazone (Compound) causes Constipation (Side Effect) and Constipation (Side Effect) is caused by Dapagliflozin (Compound)
Metolazone may cause a mod... |
DB00575 | DB13074 | 1,020 | 877 | [
"DDInter412",
"DDInter1110"
] | Clonidine | Macimorelin | Clonidine is an imidazole derivate that acts as an agonist of alpha-2 adrenoceptors. This activity is useful for the treatment of hypertension, severe pain, and ADHD.[L7237,L7240,L7243,L7246] Clonidine was granted FDA approval on 3 September 1974. | Macimorelin, a novel and orally active ghrelin mimetic that stimulates GH secretion, is used in the diagnosis of adult GH deficiency (AGHD). More specifically, macimorelin is a peptidomimetic growth hormone secretagogue (GHS) that acts as an agonist of GH secretagogue receptor, or ghrelin receptor (GHS-R1a) to dose-dep... | Moderate | 1 | [
[
[
1020,
24,
877
]
],
[
[
1020,
63,
176
],
[
176,
24,
877
]
],
[
[
1020,
24,
1042
],
[
1042,
24,
877
]
],
[
[
1020,
1,
1512
],
[
1512,
... | [
[
[
"Clonidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Macimorelin"
]
],
[
[
"Clonidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Insulin glargine"
],
... | Clonidine may cause a moderate interaction that could exacerbate diseases when taken with Insulin glargine and Insulin glargine may cause a moderate interaction that could exacerbate diseases when taken with Macimorelin
Clonidine may cause a moderate interaction that could exacerbate diseases when taken with Tetracosac... |
DB00258 | DB00451 | 666 | 542 | [
"DDInter270",
"DDInter1064"
] | Calcium acetate | Levothyroxine | The chemical compound calcium acetate is the calcium salt of acetic acid. It has been commonly referred to as the acetate of lime. The anhydrous form is very hygroscopic, therefore the monohydrate is the common form. | Levothyroxine is a synthetically produced form of thyroxine, a major endogenous hormone secreted by the thyroid gland. Also known as L-thyroxine or the brand name product Synthroid, levothyroxine is used primarily to treat hypothyroidism, a condition where the thyroid gland is no longer able to produce sufficient quant... | Moderate | 1 | [
[
[
666,
24,
542
]
],
[
[
666,
24,
624
],
[
624,
1,
542
]
],
[
[
666,
21,
28722
],
[
28722,
60,
542
]
],
[
[
666,
24,
88
],
[
88,
23... | [
[
[
"Calcium acetate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Levothyroxine"
]
],
[
[
"Calcium acetate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Liotrix"
]... | Calcium acetate may cause a moderate interaction that could exacerbate diseases when taken with Liotrix and Liotrix (Compound) resembles Levothyroxine (Compound)
Calcium acetate (Compound) causes Nausea (Side Effect) and Nausea (Side Effect) is caused by Levothyroxine (Compound)
Calcium acetate may cause a moderate int... |
DB00163 | DB00888 | 1,461 | 1,001 | [
"DDInter1943",
"DDInter1133"
] | Vitamin E | Mechlorethamine | In 1922, vitamin E was demonstrated to be an essential nutrient. Vitamin E is a term used to describe 8 different fat soluble tocopherols and tocotrienols, alpha-tocopherol being the most biologically active. Vitamin E acts as an antioxidant, protecting cell membranes from oxidative damage. The antioxidant effects are ... | A vesicant and necrotizing irritant destructive to mucous membranes, mechlorethamine is an alkylating drug. It was formerly used as a war gas. The hydrochloride is used as an antineoplastic in Hodgkin's disease and lymphomas. It causes severe gastrointestinal and bone marrow damage. The FDA granted marketing approval f... | Moderate | 1 | [
[
[
1461,
24,
1001
]
],
[
[
1461,
24,
450
],
[
450,
1,
1001
]
],
[
[
1461,
24,
126
],
[
126,
23,
1001
]
],
[
[
1461,
24,
51
],
[
51,
... | [
[
[
"Vitamin E",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mechlorethamine"
]
],
[
[
"Vitamin E",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cyclophosphamide"
],... | Vitamin E may cause a moderate interaction that could exacerbate diseases when taken with Cyclophosphamide and Cyclophosphamide (Compound) resembles Mechlorethamine (Compound)
Vitamin E may cause a moderate interaction that could exacerbate diseases when taken with Warfarin and Warfarin may cause a minor interaction th... |
DB00006 | DB08875 | 942 | 1,618 | [
"DDInter217",
"DDInter262"
] | Bivalirudin | Cabozantinib | Bivalirudin is a synthetic 20 residue peptide (thrombin inhibitor) which reversibly inhibits thrombin. Once bound to the active site, thrombin cannot activate fibrinogen into fibrin, the crucial step in the formation of thrombus. It is administered intravenously. Because it can cause blood stagnation, it is important t... | Cabozantinib was first approved in 2012 and is a non-specific tyrosine kinase inhibitor. It was initially approved in the US under the brand name Cometriq, which is indicated for the treatment of metastatic medullary thyroid cancer. In 2016, a capsule formulation (Cabometyx) was approved for the treatment of advanced r... | Major | 2 | [
[
[
942,
25,
1618
]
],
[
[
942,
24,
41
],
[
41,
63,
1618
]
],
[
[
942,
25,
283
],
[
283,
63,
1618
]
],
[
[
942,
24,
222
],
[
222,
24... | [
[
[
"Bivalirudin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cabozantinib"
]
],
[
[
"Bivalirudin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Levomilnacipran"
],
[
"L... | Bivalirudin may cause a moderate interaction that could exacerbate diseases when taken with Levomilnacipran and Levomilnacipran may cause a moderate interaction that could exacerbate diseases when taken with Cabozantinib
Bivalirudin may lead to a major life threatening interaction when taken with Fedratinib and Fedrati... |
DB01041 | DB11796 | 770 | 1,612 | [
"DDInter1789",
"DDInter786"
] | Thalidomide | Fostemsavir | A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, thalidomide was withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of inflammatory disorders and cancers. Thalidomide displays immunosuppressive and anti-angiogenic activity through modulating ... | Fostemsavir is the phosphonooxymethyl prodrug of temsavir, a novel HIV-1 attachment inhibitor. It binds to and inhibits the activity of gp120, a subunit within the HIV-1 gp160 envelope glycoprotein that facilitates the attachment of HIV-1 to host cell CD4 receptors - in doing so, temsavir prevents the first step in the... | Moderate | 1 | [
[
[
770,
24,
1612
]
],
[
[
770,
24,
1476
],
[
1476,
62,
1612
]
],
[
[
770,
25,
1220
],
[
1220,
23,
1612
]
],
[
[
770,
63,
112
],
[
112,
... | [
[
[
"Thalidomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fostemsavir"
]
],
[
[
"Thalidomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brigatinib"
],
[... | Thalidomide may cause a moderate interaction that could exacerbate diseases when taken with Brigatinib and Brigatinib may cause a minor interaction that can limit clinical effects when taken with Fostemsavir
Thalidomide may lead to a major life threatening interaction when taken with Dexamethasone and Dexamethasone may... |
DB00911 | DB06772 | 458 | 310 | [
"DDInter1811",
"DDInter259"
] | Tinidazole | Cabazitaxel | A nitroimidazole antitrichomonal agent effective against _Trichomonas vaginalis_, _Entamoeba histolytica_, and _Giardia lamblia_ infections. | Cabazitaxel is a taxoid synthesized from 10-deacetylbaccatin III, a compound isolated from the yew tree. As a second-generation semisynthetic microtubule inhibitor, cabazitaxel stabilizes microtubules and induces tumour cell death. Due to its low affinity for the P-glycoprotein (P-gp) efflux pump, cabazitaxel can more ... | Moderate | 1 | [
[
[
458,
24,
310
]
],
[
[
458,
24,
973
],
[
973,
24,
310
]
],
[
[
458,
6,
8374
],
[
8374,
45,
310
]
],
[
[
458,
21,
28701
],
[
28701,
... | [
[
[
"Tinidazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cabazitaxel"
]
],
[
[
"Tinidazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Paclitaxel"
],
[
... | Tinidazole may cause a moderate interaction that could exacerbate diseases when taken with Paclitaxel and Paclitaxel may cause a moderate interaction that could exacerbate diseases when taken with Cabazitaxel
Tinidazole (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Cabazitaxel (Compound)
Tinidazole (Comp... |
DB00857 | DB01097 | 1,387 | 1,377 | [
"DDInter1768",
"DDInter1033"
] | Terbinafine | Leflunomide | Terbinafine hydrochloride (Lamisil) is a synthetic allylamine antifungal.[L9065,L9068] It is highly lipophilic in nature and tends to accumulate in skin, nails, and fatty tissues. Like other allylamines, terbinafine inhibits ergosterol synthesis by inhibiting the fungal squalene monooxygenase (also called squalene epox... | Leflunomide is a pyrimidine synthesis inhibitor belonging to the DMARD (disease-modifying antirheumatic drug) class of drugs, which are chemically and pharmacologically very heterogeneous. Leflunomide was approved by FDA and in many other countries (e.g., Canada, Europe) in 1999. | Major | 2 | [
[
[
1387,
25,
1377
]
],
[
[
1387,
6,
6017
],
[
6017,
45,
1377
]
],
[
[
1387,
18,
14025
],
[
14025,
57,
1377
]
],
[
[
1387,
21,
29062
],
[
... | [
[
[
"Terbinafine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Leflunomide"
]
],
[
[
"Terbinafine",
"{u} (Compound) binds {v} (Gene)",
"CYP2C9"
],
[
"CYP2C9",
"{u} (Gene) is bound by {v} (Compound)",
"Lefl... | Terbinafine (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Leflunomide (Compound)
Terbinafine (Compound) downregulates ACOT9 (Gene) and ACOT9 (Gene) is downregulated by Leflunomide (Compound)
Terbinafine (Compound) causes Neutropenia (Side Effect) and Neutropenia (Side Effect) is caused by Leflunomide (Co... |
DB00076 | DB01118 | 1,352 | 33 | [
"DDInter555",
"DDInter76"
] | Digoxin Immune Fab (Ovine) | Amiodarone | Digoxin Immune Fab is a sheep antibody (26-10) FAB fragment from sheep immunized with the digoxin derivative Digoxindicarboxymethylamine. It is used as an antidote for overdose of digoxin. | Amiodarone is a benzofuran derivative, anti-arrhythmic drug used commonly in a variety of settings. Most known for its approved indication in life-threatening ventricular arrhythmias, it is also used off-label in the outpatient and inpatient setting for atrial fibrillation. Because of its ability to cause serious toxic... | Major | 2 | [
[
[
1352,
25,
33
]
],
[
[
1352,
25,
540
],
[
540,
1,
33
]
],
[
[
1352,
25,
57
],
[
57,
64,
33
]
],
[
[
1352,
25,
540
],
[
540,
6,
... | [
[
[
"Digoxin Immune Fab (Ovine)",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Amiodarone"
]
],
[
[
"Digoxin Immune Fab (Ovine)",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dronedarone"
],
[... | Digoxin Immune Fab (Ovine) may lead to a major life threatening interaction when taken with Dronedarone and Dronedarone (Compound) resembles Amiodarone (Compound)
Digoxin Immune Fab (Ovine) may lead to a major life threatening interaction when taken with Arsenic trioxide and Arsenic trioxide may lead to a major life th... |
DB00758 | DB00939 | 1,347 | 1,338 | [
"DDInter413",
"DDInter1135"
] | Clopidogrel | Meclofenamic acid | Clopidogrel is a prodrug of a platelet inhibitor used to reduce the risk of myocardial infarction and stroke.[A180508,L7213] Clopidogrel is indicated to reduce the risk of myocardial infarction for patients with non-ST elevated acute coronary syndrome (ACS), patients with ST-elevated myocardial infarction, and in recen... | A non-steroidal anti-inflammatory agent with antipyretic and antigranulation activities. It also inhibits prostaglandin biosynthesis. | Moderate | 1 | [
[
[
1347,
24,
1338
]
],
[
[
1347,
24,
1479
],
[
1479,
63,
1338
]
],
[
[
1347,
21,
28900
],
[
28900,
60,
1338
]
],
[
[
1347,
63,
752
],
[
7... | [
[
[
"Clopidogrel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Meclofenamic acid"
]
],
[
[
"Clopidogrel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Acetylsalicylic ac... | Clopidogrel may cause a moderate interaction that could exacerbate diseases when taken with Acetylsalicylic acid and Acetylsalicylic acid may cause a moderate interaction that could exacerbate diseases when taken with Meclofenamic acid
Clopidogrel (Compound) causes Abdominal pain (Side Effect) and Abdominal pain (Side ... |
DB00059 | DB14783 | 1,560 | 287 | [
"DDInter1404",
"DDInter574"
] | Pegaspargase | Diroximel fumarate | Pegaspargase is a conjugate of monomethoxypolyethylene glycol (mPEG) and L-asparaginase (L-asparagine amidohydrolase), an asparagine-specific enzyme that converts L-asparagine into aspartic acid and ammonia. Asparagine is an amino acid that is vital for cell survival. In humans, most normal tissues can produce asparagi... | Multiple Sclerosis (MS) is a chronic, debilitating neurological disease that can lead to profound cognitive and physical symptoms, severely affecting quality of life. It is the main cause of neurological disability not caused by trauma in the young adult population of both North America and Europe. Relapsing-remitting ... | Moderate | 1 | [
[
[
1560,
24,
287
]
],
[
[
1560,
25,
1101
],
[
1101,
24,
287
]
],
[
[
1560,
24,
384
],
[
384,
24,
287
]
],
[
[
1560,
63,
268
],
[
268,
... | [
[
[
"Pegaspargase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diroximel fumarate"
]
],
[
[
"Pegaspargase",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Bexarotene"
],
[
... | Pegaspargase may lead to a major life threatening interaction when taken with Bexarotene and Bexarotene may cause a moderate interaction that could exacerbate diseases when taken with Diroximel fumarate
Pegaspargase may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib and Idelalisi... |
DB09237 | DB13142 | 1,586 | 841 | [
"DDInter1045",
"DDInter274"
] | Levamlodipine | Calcium glubionate anhydrous | Levamlodipine, also known as S-amlodipine, is a pharmacologically active enantiomer of [amlodipine], an antihypertensive medication. Levamlodipine belongs to the dihydropyridine group of calcium channel blockers. This medication was first marketed in Russia and India before being granted FDA approval. The names S-amlod... | Calcium glubionate (or glubionate calcium) is a mineral supplement to prevent or treat low blood calcium levels in people who do not get enough calcium from their diets. | Moderate | 1 | [
[
[
1586,
24,
841
]
],
[
[
1586,
63,
1053
],
[
1053,
23,
255
],
[
255,
24,
841
]
],
[
[
1586,
63,
1053
],
[
1053,
24,
762
],
[
762,
24,
... | [
[
[
"Levamlodipine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Calcium glubionate anhydrous"
]
],
[
[
"Levamlodipine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pro... | Levamlodipine may cause a moderate interaction that could exacerbate diseases when taken with Procarbazine and Procarbazine may cause a minor interaction that can limit clinical effects when taken with Delafloxacin and Delafloxacin may cause a moderate interaction that could exacerbate diseases when taken with Calcium ... |
DB01365 | DB09564 | 280 | 1,296 | [
"DDInter1151",
"DDInter930"
] | Mephentermine | Insulin degludec | A sympathomimetic agent with mainly indirect effects on adrenergic receptors. It is used to maintain blood pressure in hypotensive states, for example, following spinal anesthesia. Although the central stimulant effects of mephentermine are much less than those of amphetamine, its use may lead to amphetamine-type depen... | Insulin degludec is an ultra-long-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes.[A18561,A18562,A18563,A18564,A174934] Insulin is typically prescribed for the management of diabetes mellitus to mimic the activity of endogenously produced human insulin, a peptide horm... | Moderate | 1 | [
[
[
280,
24,
1296
]
],
[
[
280,
63,
1411
],
[
1411,
24,
1296
]
],
[
[
280,
24,
659
],
[
659,
24,
1296
]
],
[
[
280,
40,
551
],
[
551,
... | [
[
[
"Mephentermine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Insulin degludec"
]
],
[
[
"Mephentermine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tolbutamide"
... | Mephentermine may cause a moderate interaction that could exacerbate diseases when taken with Tolbutamide and Tolbutamide may cause a moderate interaction that could exacerbate diseases when taken with Insulin degludec
Mephentermine may cause a moderate interaction that could exacerbate diseases when taken with Vilante... |
DB00470 | DB09034 | 530 | 1,313 | [
"DDInter601",
"DDInter1733"
] | Dronabinol | Suvorexant | Dronabinol (marketed as Marinol) is a synthetic form of delta-9-tetrahydrocannabinol (Δ⁹-THC), the primary psychoactive component of cannabis (marijuana). THC demonstrates its effects through weak partial agonist activity at Cannabinoid-1 (CB1R) and Cannabinoid-2 (CB2R) receptors, which results in the well-known effect... | Suvorexant is a selective dual antagonist of orexin receptors OX1R and OX2R that promotes sleep by reducing wakefulness and arousal. It has been approved for the treatment of insomnia. | Moderate | 1 | [
[
[
530,
24,
1313
]
],
[
[
530,
24,
649
],
[
649,
24,
1313
]
],
[
[
530,
24,
1619
],
[
1619,
63,
1313
]
],
[
[
530,
63,
701
],
[
701,
... | [
[
[
"Dronabinol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Suvorexant"
]
],
[
[
"Dronabinol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clofedanol"
],
[
... | Dronabinol may cause a moderate interaction that could exacerbate diseases when taken with Clofedanol and Clofedanol may cause a moderate interaction that could exacerbate diseases when taken with Suvorexant
Dronabinol may cause a moderate interaction that could exacerbate diseases when taken with Rucaparib and Rucapar... |
DB00460 | DB01259 | 612 | 392 | [
"DDInter1929",
"DDInter1024"
] | Verteporfin | Lapatinib | Verteporfin, marketed as Visudyne, is a benzoporphyrin derivative. It is used as a photosensitizer in photodynamic therapy to eliminate abnormal blood vessels in wet form macular degeneration. Verteporfin accumulates in these abnormal blood vessels and, when stimulated by nonthermal red light with a wavelength of 693 n... | Lapatinib is an anti-cancer drug developed by GlaxoSmithKline (GSK) as a treatment for solid tumours such as breast and lung cancer. It was approved by the FDA on March 13, 2007, for use in patients with advanced metastatic breast cancer in conjunction with the chemotherapy drug capecitabine. Lapatinib is a human epide... | Moderate | 1 | [
[
[
612,
24,
392
]
],
[
[
612,
21,
28883
],
[
28883,
60,
392
]
],
[
[
612,
24,
918
],
[
918,
24,
392
]
],
[
[
612,
63,
10
],
[
10,
2... | [
[
[
"Verteporfin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lapatinib"
]
],
[
[
"Verteporfin",
"{u} (Compound) causes {v} (Side Effect)",
"Skin disorder"
],
[
"Skin disorder",
"{u} (Side Effect... | Verteporfin (Compound) causes Skin disorder (Side Effect) and Skin disorder (Side Effect) is caused by Lapatinib (Compound)
Verteporfin may cause a moderate interaction that could exacerbate diseases when taken with Bicalutamide and Bicalutamide may cause a moderate interaction that could exacerbate diseases when taken... |
DB00619 | DB11652 | 1,419 | 1,155 | [
"DDInter909",
"DDInter1891"
] | Imatinib | Tucatinib | Imatinib is a small molecule kinase inhibitor that revolutionized the treatment of cancer, particularly chronic myeloid leukemia, in 2001. It was deemed a "miracle drug" due to its clinical success, as oncologist Dr. Brian noted that "complete hematologic responses were observed in 53 of 54 patients with CML treated wi... | Tucatinib is a kinase inhibitor drug used with [trastuzumab] and [capecitabine] in the treatment of unresectable or metastatic HER-2 positive breast cancer. It was developed by Seattle Genetics and approved by the FDA on April 17, 2020. Tucatinib is a promising new treatment for patients with metastatic breast cancer w... | Moderate | 1 | [
[
[
1419,
24,
1155
]
],
[
[
1419,
23,
222
],
[
222,
23,
1155
]
],
[
[
1419,
62,
1101
],
[
1101,
23,
1155
]
],
[
[
1419,
63,
1424
],
[
1424... | [
[
[
"Imatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tucatinib"
]
],
[
[
"Imatinib",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Sibutramine"
],
[
"S... | Imatinib may cause a minor interaction that can limit clinical effects when taken with Sibutramine and Sibutramine may cause a minor interaction that can limit clinical effects when taken with Tucatinib
Imatinib may cause a minor interaction that can limit clinical effects when taken with Bexarotene and Bexarotene may ... |
DB00495 | DB06273 | 139 | 980 | [
"DDInter1961",
"DDInter1824"
] | Zidovudine | Tocilizumab | A dideoxynucleoside compound in which the 3'-hydroxy group on the sugar moiety has been replaced by an azido group. This modification prevents the formation of phosphodiester linkages which are needed for the completion of nucleic acid chains. The compound is a potent inhibitor of HIV replication, acting as a chain... | Tocilizumab is a recombinant humanized monoclonal antibody IL-6 receptor inhibitor used to treat inflammatory and autoimmune conditions. It was first described in the literature in 2003 when Chugai, a subsidiary of Roche began developing IL-6 inhibiting monoclonal antibodies. Tocilizumab was granted FDA approval on 8 J... | Moderate | 1 | [
[
[
139,
24,
980
]
],
[
[
139,
24,
309
],
[
309,
24,
980
]
],
[
[
139,
24,
850
],
[
850,
63,
980
]
],
[
[
139,
25,
1613
],
[
1613,
6... | [
[
[
"Zidovudine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tocilizumab"
]
],
[
[
"Zidovudine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ixabepilone"
],
[
... | Zidovudine may cause a moderate interaction that could exacerbate diseases when taken with Ixabepilone and Ixabepilone may cause a moderate interaction that could exacerbate diseases when taken with Tocilizumab
Zidovudine may cause a moderate interaction that could exacerbate diseases when taken with Brentuximab vedoti... |
DB01218 | DB09293 | 1,493 | 116 | [
"DDInter852",
"DDInter954"
] | Halofantrine | Iodide I-131 | Halofantrine is an antimalarial. It belongs to the phenanthrene class of compounds that includes quinine and lumefantrine. It appears to inhibit polymerisation of heme molecules (by the parasite enzyme "heme polymerase"), resulting in the parasite being poisoned by its own waste. Halofantrine has been shown to preferen... | Iodide I-131 (as Sodium iodide I-131) is a radioisotopic drug used for the treatment and palliation of thyroid malignancy. Iodine-131 is notable for causing mutation and death in cells that it penetrates, which is due to its mode of beta decay. As a result of beta decay, approximately 10% of its energy and radiation do... | Moderate | 1 | [
[
[
1493,
24,
116
]
],
[
[
1493,
25,
1487
],
[
1487,
24,
116
]
],
[
[
1493,
64,
252
],
[
252,
24,
116
]
],
[
[
1493,
62,
1247
],
[
1247,
... | [
[
[
"Halofantrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Iodide I-131"
]
],
[
[
"Halofantrine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Hydroxychloroquine"
],
[
... | Halofantrine may lead to a major life threatening interaction when taken with Hydroxychloroquine and Hydroxychloroquine may cause a moderate interaction that could exacerbate diseases when taken with Iodide I-131
Halofantrine may lead to a major life threatening interaction when taken with Hydroxyzine and Hydroxyzine m... |
DB00372 | DB01320 | 999 | 651 | [
"DDInter1793",
"DDInter783"
] | Thiethylperazine | Fosphenytoin | A dopamine antagonist that is particularly useful in treating the nausea and vomiting associated with anesthesia, mildly emetic cancer chemotherapy agents, radiation therapy, and toxins. This piperazine phenothiazine does not prevent vertigo or motion sickness. (From AMA Drug Evaluations Annual, 1994, p457) | Fosphenytoin is a water-soluble phenytoin prodrug used only in hospitals for the treatment of epileptic seizures. It works by slowing down impulses in the brain that cause seizures. Its main mechanism is to block frequency-dependent, use-dependent and voltage-dependent neuronal sodium channels, and therefore limit repe... | Moderate | 1 | [
[
[
999,
24,
651
]
],
[
[
999,
63,
362
],
[
362,
1,
651
]
],
[
[
999,
24,
5
],
[
5,
63,
651
]
],
[
[
999,
24,
1264
],
[
1264,
24,
... | [
[
[
"Thiethylperazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fosphenytoin"
]
],
[
[
"Thiethylperazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phenytoin"
... | Thiethylperazine may cause a moderate interaction that could exacerbate diseases when taken with Phenytoin and Phenytoin (Compound) resembles Fosphenytoin (Compound)
Thiethylperazine may cause a moderate interaction that could exacerbate diseases when taken with Liraglutide and Liraglutide may cause a moderate interact... |
DB00085 | DB00650 | 639 | 1,147 | [
"DDInter1384",
"DDInter1041"
] | Pancrelipase | Leucovorin | Pancrelipase, in general, is composed of a mixture of pancreatic enzymes which include amylases, lipases, and proteases. These enzymes are extracted from porcine pancreatic glands. The pancrelipase mixture was developed by Ortho-McNeil-Janssen Pharmaceuticals, Inc and FDA approved on April 12, 2010. For further informa... | Folinic Acid (also known as 5-formyl tetrahydrofolic acid or leucovorin) is the 5-formyl derivative of tetrahydrofolic acid, a necessary co-factor in the body. Commercially available leucovorin is composed of a 1:1 racemic mixture of the dextrorotary and levorotary isomers, while levoleucovorin contains only the pharma... | Moderate | 1 | [
[
[
639,
24,
1147
]
],
[
[
639,
24,
356
],
[
356,
1,
1147
]
],
[
[
639,
24,
1596
],
[
1596,
21,
29243
],
[
29243,
60,
1147
]
],
[
[
639,
... | [
[
[
"Pancrelipase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Leucovorin"
]
],
[
[
"Pancrelipase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Folic acid"
],
... | Pancrelipase may cause a moderate interaction that could exacerbate diseases when taken with Folic acid and Folic acid (Compound) resembles Leucovorin (Compound)
Pancrelipase may cause a moderate interaction that could exacerbate diseases when taken with Iron and Iron (Compound) causes Wheezing (Side Effect) and Wheezi... |
DB00912 | DB04855 | 473 | 540 | [
"DDInter1581",
"DDInter602"
] | Repaglinide | Dronedarone | Repaglinide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It belongs to the meglitinide class of short-acting insulin secretagogues, which act by binding to β cells of the pancreas to stimulate insulin release. Repaglinide induces an early insulin response... | Dronedarone is a Class III antiarrhythmic drug that works to restore the normal sinus rhythm in patients with paroxysmal or persistent atrial fibrillation. Atrial fibrillation is a common sustained arrhythmia where the treatment primarily focuses on stroke prevention and symptom management. It is managed by rate contro... | Moderate | 1 | [
[
[
473,
24,
540
]
],
[
[
473,
24,
33
],
[
33,
40,
540
]
],
[
[
473,
6,
8374
],
[
8374,
45,
540
]
],
[
[
473,
21,
28883
],
[
28883,
... | [
[
[
"Repaglinide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dronedarone"
]
],
[
[
"Repaglinide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Amiodarone"
],
[... | Repaglinide may cause a moderate interaction that could exacerbate diseases when taken with Amiodarone and Amiodarone (Compound) resembles Dronedarone (Compound)
Repaglinide (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Dronedarone (Compound)
Repaglinide (Compound) causes Skin disorder (Side Effect) and ... |
DB00619 | DB06643 | 1,419 | 1,136 | [
"DDInter909",
"DDInter500"
] | Imatinib | Denosumab | Imatinib is a small molecule kinase inhibitor that revolutionized the treatment of cancer, particularly chronic myeloid leukemia, in 2001. It was deemed a "miracle drug" due to its clinical success, as oncologist Dr. Brian noted that "complete hematologic responses were observed in 53 of 54 patients with CML treated wi... | Denosumab is a novel, fully human IgG2 monoclonal antibody specific to receptor activator of nuclear factor kappa-B ligand (RANKL), suppresses bone resorption via inhibiting RANK-mediated activation of osteoclasts. It is the first and currently the only RANKL inhibitor approved to prevent osteoclast-mediated bone loss.... | Moderate | 1 | [
[
[
1419,
24,
1136
]
],
[
[
1419,
24,
1213
],
[
1213,
24,
1136
]
],
[
[
1419,
63,
1555
],
[
1555,
24,
1136
]
],
[
[
1419,
25,
1377
],
[
13... | [
[
[
"Imatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Denosumab"
]
],
[
[
"Imatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dasatinib"
],
[
"D... | Imatinib may cause a moderate interaction that could exacerbate diseases when taken with Dasatinib and Dasatinib may cause a moderate interaction that could exacerbate diseases when taken with Denosumab
Imatinib may cause a moderate interaction that could exacerbate diseases when taken with Oxaliplatin and Oxaliplatin ... |
DB00153 | DB01324 | 1,331 | 178 | [
"DDInter662",
"DDInter1490"
] | Ergocalciferol | Polythiazide | Ergocalciferol is an inactivated vitamin D analog. It is synthesized by some plants in the presence of UVB light. The production of ergocalciferol was prompted by the identification of dietary deficiency, more specifically vitamin D, as the main causative factor for the development of rickets. Ergocalciferol was isolat... | A thiazide diuretic with actions and uses similar to those of hydrochlorothiazide. (From Martindale, The Extra Pharmacopoeia, 30th ed, p826) | Moderate | 1 | [
[
[
1331,
24,
178
]
],
[
[
1331,
24,
674
],
[
674,
40,
178
]
],
[
[
1331,
21,
28714
],
[
28714,
60,
178
]
],
[
[
1331,
24,
286
],
[
286,
... | [
[
[
"Ergocalciferol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Polythiazide"
]
],
[
[
"Ergocalciferol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trichlormethiazid... | Ergocalciferol may cause a moderate interaction that could exacerbate diseases when taken with Trichlormethiazide and Trichlormethiazide (Compound) resembles Polythiazide (Compound)
Ergocalciferol (Compound) causes Asthenia (Side Effect) and Asthenia (Side Effect) is caused by Polythiazide (Compound)
Ergocalciferol may... |
DB00367 | DB06292 | 566 | 549 | [
"DDInter1061",
"DDInter474"
] | Levonorgestrel | Dapagliflozin | Levonorgestrel (LNG) is a synthetic progestogen similar to [Progesterone] used in contraception and hormone therapy.[A181988,T659] Also known as Plan B, it is used as a single agent in emergency contraception, and as a hormonal contraceptive released from an intrauterine device, commonly referred to as an IUD. Some of ... | Dapagliflozin is a sodium-glucose cotransporter 2 (SGLT2) inhibitor, and it was the first SLGT2 inhibitor to be approved. indicated for managing diabetes mellitus type 2. When combined with diet and exercise in adults, dapagliflozin helps to improve glycemic control by inhibiting glucose reabsorption in the proximal tu... | Moderate | 1 | [
[
[
566,
24,
549
]
],
[
[
566,
24,
1344
],
[
1344,
40,
549
]
],
[
[
566,
6,
8374
],
[
8374,
45,
549
]
],
[
[
566,
21,
28882
],
[
28882,
... | [
[
[
"Levonorgestrel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dapagliflozin"
]
],
[
[
"Levonorgestrel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Canagliflozin"
... | Levonorgestrel may cause a moderate interaction that could exacerbate diseases when taken with Canagliflozin and Canagliflozin (Compound) resembles Dapagliflozin (Compound)
Levonorgestrel (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Dapagliflozin (Compound)
Levonorgestrel (Compound) causes Body temperat... |
DB01064 | DB01182 | 1,148 | 371 | [
"DDInter987",
"DDInter1534"
] | Isoprenaline | Propafenone | Isoprenaline is a non-selective beta adrenergic receptor agonist indicated to treat heart block, Adams-Stokes attacks, bronchospasm in anesthesia, cadiac arrest, hypovolemic shocks, septic shock, hypoperfusion, congestive hear failure, and cardiogenic shock.[A15638,L33160] Isoprenaline research in the 1940s found that ... | An antiarrhythmia agent that is particularly effective in ventricular arrhythmias. It also has weak beta-blocking activity. The drug is generally well tolerated. | Moderate | 1 | [
[
[
1148,
24,
371
]
],
[
[
1148,
63,
847
],
[
847,
1,
371
]
],
[
[
1148,
24,
772
],
[
772,
40,
371
]
],
[
[
1148,
63,
1523
],
[
1523,
... | [
[
[
"Isoprenaline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Propafenone"
]
],
[
[
"Isoprenaline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Atomoxetine"
],
... | Isoprenaline may cause a moderate interaction that could exacerbate diseases when taken with Atomoxetine and Atomoxetine (Compound) resembles Propafenone (Compound)
Isoprenaline may cause a moderate interaction that could exacerbate diseases when taken with Carvedilol and Carvedilol (Compound) resembles Propafenone (Co... |
DB00860 | DB01097 | 891 | 1,377 | [
"DDInter1513",
"DDInter1033"
] | Prednisolone | Leflunomide | Prednisolone is a glucocorticoid similar to [cortisol] used for its anti-inflammatory, immunosuppressive, anti-neoplastic, and vasoconstrictive effects. Prednisolone was granted FDA approval on 21 June 1955. | Leflunomide is a pyrimidine synthesis inhibitor belonging to the DMARD (disease-modifying antirheumatic drug) class of drugs, which are chemically and pharmacologically very heterogeneous. Leflunomide was approved by FDA and in many other countries (e.g., Canada, Europe) in 1999. | Major | 2 | [
[
[
891,
25,
1377
]
],
[
[
891,
5,
11577
],
[
11577,
44,
1377
]
],
[
[
891,
21,
28701
],
[
28701,
60,
1377
]
],
[
[
891,
62,
1461
],
[
146... | [
[
[
"Prednisolone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Leflunomide"
]
],
[
[
"Prednisolone",
"{u} (Compound) treats {v} (Disease)",
"rheumatoid arthritis"
],
[
"rheumatoid arthritis",
"{u} (Disease) is ... | Prednisolone (Compound) treats rheumatoid arthritis (Disease) and rheumatoid arthritis (Disease) is treated by Leflunomide (Compound)
Prednisolone (Compound) causes Discomfort (Side Effect) and Discomfort (Side Effect) is caused by Leflunomide (Compound)
Prednisolone may cause a minor interaction that can limit clinica... |
DB00794 | DB01229 | 759 | 973 | [
"DDInter1521",
"DDInter1378"
] | Primidone | Paclitaxel (protein-bound) | Primidone is an anticonvulsant used to treat essential tremor as well as grand mal, psychomotor, and focal epileptic seizures. Primidone was developed by J Yule Bogue and H C Carrington in 1949. Primidone was granted FDA Approval on 8 March 1954. | Paclitaxel can cause developmental toxicity, female reproductive toxicity and male reproductive toxicity according to state or federal government labeling requirements. | Moderate | 1 | [
[
[
759,
24,
973
]
],
[
[
759,
24,
310
],
[
310,
63,
973
]
],
[
[
759,
6,
8374
],
[
8374,
45,
973
]
],
[
[
759,
18,
3741
],
[
3741,
... | [
[
[
"Primidone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Paclitaxel"
]
],
[
[
"Primidone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cabazitaxel"
],
[
... | Primidone may cause a moderate interaction that could exacerbate diseases when taken with Paclitaxel
Primidone may cause a moderate interaction that could exacerbate diseases when taken with Cabazitaxel and Cabazitaxel may cause a moderate interaction that could exacerbate diseases when taken with Paclitaxel
Primidone ... |
DB01067 | DB11827 | 959 | 433 | [
"DDInter826",
"DDInter669"
] | Glipizide | Ertugliflozin | Glipizide is an oral hypoglycemic agent in the second-generation sulfonylurea drug class that is used to control blood sugar levels in patients with type 2 diabetes mellitus. It was first introduced in 1984 and is available in various countries including Canada and the U.S. According to the 2018 Clinical Practice Guide... | Ertugliflozin is a sodium-dependent glucose cotransporter-2 (SGLT2) inhibitor used to treat type II diabetes mellitus. It works to block glucose reabsorption from the glomerulus. Ertugliflozin was first approved by the FDA in December 2017.[A261951, L1132] It was also approved by the European Commission in March 2018. | Moderate | 1 | [
[
[
959,
24,
433
]
],
[
[
959,
62,
1103
],
[
1103,
23,
433
]
],
[
[
959,
64,
646
],
[
646,
24,
433
]
],
[
[
959,
63,
1020
],
[
1020,
... | [
[
[
"Glipizide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ertugliflozin"
]
],
[
[
"Glipizide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Amcinonide"
],
[
... | Glipizide may cause a minor interaction that can limit clinical effects when taken with Amcinonide and Amcinonide may cause a minor interaction that can limit clinical effects when taken with Ertugliflozin
Glipizide may lead to a major life threatening interaction when taken with Cinoxacin and Cinoxacin may cause a mod... |
DB00872 | DB01006 | 1,080 | 300 | [
"DDInter438",
"DDInter1040"
] | Conivaptan | Letrozole | Conivaptan is a non-peptide inhibitor of antidiuretic hormone (vasopressin). It was approved in 2004 for hyponatremia (low blood sodium levels) caused by syndrome of inappropriate antidiuretic hormone (SIADH). Conivaptan inhibits both isotypes of the vasopressin receptor (V1a and V2). | Letrozole, or CGS 20267, is an oral non-steroidal type II aromatase inhibitor first described in the literature in 1990.[A190543,A1559,L11623,L11626] It is a third generation aromatase inhibitor like [exemestane] and [anastrozole], meaning it does not significantly affect cortisol, aldosterone, and thyroxine. Letrozole... | Moderate | 1 | [
[
[
1080,
24,
300
]
],
[
[
1080,
6,
8374
],
[
8374,
45,
300
]
],
[
[
1080,
21,
28646
],
[
28646,
60,
300
]
],
[
[
1080,
25,
478
],
[
478,
... | [
[
[
"Conivaptan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Letrozole"
]
],
[
[
"Conivaptan",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
... | Conivaptan (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Letrozole (Compound)
Conivaptan (Compound) causes Unspecified disorder of skin and subcutaneous tissue (Side Effect) and Unspecified disorder of skin and subcutaneous tissue (Side Effect) is caused by Letrozole (Compound)
Conivaptan may lead to a m... |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.